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Abstract
The aim of this study is to establish a brief screening tool to classify PD patients as PD 
with normal cognition (PD-N), PD patients with mild cognitive impairment (PD-MCI)
and PD patients with dementia (PD-D). There has been emerging evidence that the 
MoCA (Montreal Cognitive Assessment) shows potential for the brief assessment of 
cognition to differentiate among PD patients. One possible solution to further improve 
the discrimination among PD-D, PD-MCI and PD-N groups is to examine Instrumental 
Activities of Daily Living (IADL) measures in conjunction with the MoCA. A 
convenience sample of 162 patients suffering from PD and 53 volunteer control subjects 
were examined in a movement disorders center. Extensive neuropsychological testing 
was done to classify the PD patients into PD-N, PD-MCI or PD-D. The 24 patients were 
diagnosed as PD-D based on the Movement Disorders Society Task Force criteria. For 
PD-MCI, two criteria were used: 1.5SD:2 in one-domain (1.5 SD below the norms on 
two measures in at least one of four cognitive domains) and 1.5SD:1 in two-domains (1.5 
SD below normative data in at least one measure but in two domains) which made a 
diagnosis of 34 and 39 PD-MCI patients respectively. The remaining patients were 
classified as PD-N. For both the MCI criteria, the results suggest that 1) for 
discriminating PD-MCI from PD-N, the MoCA is a sufficiently suitable screening 
measure that is not improved by adding ADL measures, 2) for distinguishing PD-D from 
PD-MCI, the MoCA and the full ADL-IS questionnaire can be administered to a patient 
suffering from PD. When time is limited and depending on the possibility of answering 
the questions regarding the ADL-IS items, the MoCA along with the Muddled and 
Complex Medication ADL-IS items should be administered. When no scores are obtained 
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for Muddled, then MoCA along with Complex Medication ADL-IS item is sufficient to 
discriminate PD-D from PD-MCI. However, if no scores are obtained for Complex 
Medication item, then an average of four ADL-IS items should be taken along with the 
MoCA. This attractive brief screening tool helps in detection of cognitive impairment in 
the elderly.
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The MoCA and ADL Items separate Mild Cognitive Impairment and 
Dementia in Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, 
affecting approximately 3% of the population older than 70 years and nearly 1% of the 
population older than 55 years after Alzheimer’s disease (AD, Metzler-Baddeley, 2007).
PD is an idiopathic motor disorder that is associated with loss of dopamine cells that
leads to increasing disability, related to the presence of Lewy bodies in brain-stem nigral 
and extranigral neurons (Troster, 2008). PD is diagnosed with the following signs and 
symptoms: bradykinesia, and tremor, rigidity or unexplained postural instability 
(Guttman, Kish & Furukawa, 2003) that cannot be explained by tumour, stroke, or non-
PD signs. However, the most debilitating symptoms of PD are often non-motor 
symptoms such as cognitive and psychiatric changes that majority of PD patients often 
develop (Aarsland, 2010; Caccappolo & Marder, 2010).
Recent PD studies indicate that cognitive decline will result in a cumulative 
prevalence of dementia (PD-D) in 75-90% of PD patients (Aarsland, Andersen, Larsen, 
Lolk, & Kragh-Sorensen, 2003; Buter, van den hout, Matthews, Larsen, Brayne & 
Aarsland, 2008; Hely, Reid, Adena, Halliday & Morris, 2008). Many patients endure 
milder symptoms, often sufficient to be categorized as mild cognitive impairment (PD-
MCI), which presumably precedes the onset of dementia. Although the definition of PD-
MCI is a matter of debate (Dalrymple-Alford, Livingston, MacAskill, Graham, Melzer, 
Porter, Watts, & Anderson, 2011), the prevalence of MCI is estimated to be 
approximately 30% of non-dementia patients. About 60% of individuals with PD-MCI
may progress to dementia within four years (Caviness, Driver-Dunckley, Connor, 
Sabbagh, Hentz, Noble, Evidente, Shill & Adler, 2007; Janvin, Larsen, Aarsland, & 
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Hugdahl, 2006). This potential transition stage of PD-MCI has gained increasing interest 
in the literature, to capture the patients at increased risk for PD-D and to facilitate 
targeted intervention studies (Janvin et al., 2006; Marder, 2010).
Impaired performance on executive function in PD is often more pronounced than 
on other measures and is often regarded as a key issue in PD (Azuma, Cruz, Bayles, 
Tomoeda & Montgomery, 2003; Mosimann, Mather, Wesnes, O’Brien, Burn & McKeith, 
2004).  Conversely, visuospatial function decline is found in PD-D but perhaps not 
reliably during the early stages (Levin, Llabre, Reisman, Weiner, Sanchez-Ramos, Singer 
& Brown, 1991). In PD-MCI, impairments may be evident in one or more cognitive 
domain, such as executive function, attention, visuospatial skills and memory, but 
language and praxis are generally spared (Caviness et al., 2007; Muslimovic, Post, 
Speelman & Schmand, 2005).
The preceding summary suggests that it is essential to have good instruments that 
provide effective screening for PD-D and PD-MCI which cover a broad range of 
cognitive functions. The Movement Disorders Society Task Force (Dubois, Burn, Goetz,
Aarsland, Brown, Broe, Dickson, Duyckaerts, Cummings, Gauthier, Korczyn, Lees, 
Levy, Litvan, Mizuno, McKeith, Olanow, Poewe, Sampaio, Tolosa, & Emre, 2007; 
Emre, Aarsland, Brown, Burn, Duyckaerts, Mizuno, Broe, Cummings, Dickson, 
Gauthier, Goldman, Goetz, Korcyzn, Lees, Levy, Litvan, McKeith, Olanow, Poewe, 
Quinn, Sampaio, Tolosa, & Dubois, 2007) stated that for the diagnosis of PD-D it is 
important to have significant impairment in at least two cognitive domains, and two 
dementia assessment tests (such as Dementia Rating Scale-2 (DRS-2), Alzheimer’s 
Disease Assessment Scale-Cognition (ADAS-Cog); Harvey, Ferris, Cummings, Wesnes, 
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Hsu, Lane, & Tekin, 2009; Jurica, Leitten, & Mattis, 2001), but there must also be 
evidence of impairments in everyday function – preferably from a significant other such 
as the Activities of Daily Living – International Scale (ADL-IS; Reisberg, Finkel, 
Overall, Schmidt-Gollas, Kanowski, Lehfeld, Hulla, Sclan, Wilms, Heininger, 
Hindmarch, Stemmler, Poon, Kluger, Cooler, Bergener, Hugonot-Diener, Robert, & 
Erzigkeit, 2001) (see methods). With respect to PD-MCI, however, widely disparate 
criteria have been used many of which produce a large proportion of “false positives”
(Dalrymple-Alford et al., 2011). Irrespective of the preference of PD-MCI criteria, tools 
are needed to help better separate PD-D, PD-MCI and PD patients with generally normal 
cognition (PD-N).
Montreal Cognitive Assessment 
The Montreal Cognitive Assessment (MoCA) is one tool that may be helpful in this 
regard. The MoCA was originally developed as a brief screening instrument for mild AD 
and MCI (Nasreddine, Phillips, Be´dirian, Charbonneau, Whitehead, Collin, Cumming & 
Chertkow, 2005) and has become an increasingly popular screen for many conditions, 
especially as the MoCA is also suitable for use by nonspecialist staff (Ismail, Rajji, & 
Shulman, 2010).  The MoCA is a 30-point instrument that takes approximately 10 to 15 
minutes to administer (Appendix 1). Table 1 outlines the various domains and items 
covered by this test. The MoCA is less prone to ceiling effects than the Mini-Mental State 
Examination (MMSE; Folstein, Folstein, & McHugh, 1975) when used to detect amnesic 
MCI cases (Nasreddine et al., 2005). Despite concerns of the lack of validation, and 
sensitivity and accuracy of MMSE in the PD population, MMSE is still the most 
commonly used screen for cognitive status in PD. However, a recent Movement 
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Disorders Society (MDS) Task Force recommended use of the MoCA to screen cognition 
in PD (Chou, Amick, Brandt, Camicioli, Frei, Gitelman, Goldman, Growdon, Hurtig, 
Levin, Litvan, Marsh, Simuni, Troster, & Uc, 2010). The wider range of cognitive 
domains examined and the more demanding nature of some of its items suggests the 
MoCA may be more responsive to problems across specific domains than is the MMSE. 
Table 1
Montreal Cognitive Assessment (MoCA)
Domains Items
Visuospatial/Executive Trail making B task, Clock drawing, and 
Cube coping
Naming Animal naming
Attention Digits forward and backward, Target 
alphabet detection using tapping, and 
Serial seven’s
Language Sentence repetition, and Phonemic 
fluency
Abstraction Verbal abstraction
Short-term Memory Recall of five nouns after 5 minutes
Orientation Orientation to time and place
There has been emerging evidence that the MoCA shows potential for the brief 
assessment of cognition to differentiate PD patients with MCI from PD-N (Dalrymple-
Alford, MacAskill, Nakas, Livingston, Graham, Crucian, Melzer, Kirwan, Keenan, 
Wells, Porter, Watts, & Anderson, 2010; Nazem, Siderowf, Duda, Have, Colcher, Horn, 
Moberg, Wilkinson, Hurtig, Stern, & Weintraub, 2009; Zadikoff, Fox, Tang-Wai, 
Thomsen, de Bie, Wadia, Miyasaki, Duff-Canning, Lang, & Marras, 2008). The 
recommended MoCA cut off score of less than 26 for amnesic MCI (Nasreddine et al., 
2005) has also been found useful for PD patients (Dalrymple-Alford et al., 2010). Thus
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the crucial advantages of using the MoCA are its assessment of various cognitive 
domains, easy and rapid administration, and sensitivity to cognitive impairment in PD 
population.
At least five recent studies have examined the value of the MoCA in PD 
(Dalrymple-Alford et al., 2010; Gill, Freshman, Blender & Ravina, 2008; Hoops, Nazem, 
Siderowf, Duda, Xie, Stern & Weintraub, 2009; Nazem et al., 2009; Zadikoff et al., 
2008). The recent study evaluated the diagnostic validity of the MoCA along with the 
MMSE and the PD-focused Scales for Outcomes in PD-Cognition (SCOPA-COG), 
together with independently validated groups based on extensive neuropsychological 
testing. In this study, the MoCA performed generally better when discriminating both 
dementia and MCI in PD (Dalrymple-Alford et al., 2010). The cut-off proposed by
Dalrymple-Alford et al. (2010) for screening cognition in PD was <21 for PD-D with 
good sensitivity and high specificity (81% and 95% respectively) along with high
positive predictive value (PPV) and negative predictive value (NPV; 87% and 92%
respectively). The PD-MCI screening cut-off of <26 also had high sensitivity and good 
specificity (90% and 75% respectively) but moderate PPV (61%) and high NPV (95%). 
Other studies support the view that the MoCA might be a particularly sensitive screening 
instrument that can be used to detect mild cognitive changes in patients suffering from 
PD. For example, Hoops et al. (2009) evaluated the validity of the MoCA and the MMSE 
to detect the presence of MCI or dementia in patients suffering from PD. They found that 
the MoCA was superior as a global cognition assessment screening tool for the detection 
of MCI or dementia in PD population but the results were in convincing. Nazem and his 
collegues (2009) suggested that 52% of PD patients with a “normal” global cognition 
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score on the MMSE questionnaire had cognitive impairment using the recommended 
cuttoff of less than 26 on the MoCA. Another study reported that both MoCA and MMSE 
obtained the same high areas in the receiver operating characteristics (ROC) in 
identifying PD-MCI defined as 1.5 SD at or below normative scores on one or more tests 
of memory and executive function, but the lower range of scores (16 on the MMSE; 6 on 
the MoCA) suggests that their PD-MCI group included some PD-D patients (Gill et al., 
2008). This study by Gill et al. (2008) also indicated that the MoCA had good test-retest
reliability, inter-rater reliability and convergent validity with PD. In sum, while the
MoCA has been indicated to be better than MMSE in a number of studies, the sensitivity 
and specificity of the MoCA reported by some of these studies is poor (for example 
Hoops et al., 2009). Different criteria used to classify PD-MCI (Dalrymple-Alford et al., 
2011) can partly explain these differences but additional work is clearly warranted.
One possible solution to improve the discrimination among PD-D, PD-MCI and 
PD-N groups is to examine Instrumental Activities of Daily Living (IADL) measures in 
conjunction with the MoCA. The rationale behind examining both the MoCA and daily 
living activities is that for a diagnosis of PD-D, it is important to have evidence of decline 
in activities of daily living that the PD patients previously performed (Dubios et al., 
2007) in addition to impairments in formal neuropsychological tests. 
Activities of Daily Living
A variety of questionnaires to measure IADL are used with dementia patients. There is 
also increasing recognition that modest changes in IADL may occur in mild cognitive 
impairment (Schmitter-Edgecombe, Woo & Greeley, 2009; Li, Ng, Kua & Ko, 2006).
Key examples of IADL instruments include the Alzheimer’s Disease Cooperative Study 
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Activities of Daily living (ADCS-ADL; Galasko, Bennett, Sano, Ernesto, Thomas, 
Grudman, Ferris, & the Alxhiemers Disease Cooperative Study, 1997), the Progressive 
Deterioration Scale (PDS; Dejong, Osterlung & Roy, 1989), the Bristol Activities of 
Daily Living Scale (BADL; Bucks, Ashworth, Wilcock & Siegfried, 1996), the Lawton 
Instrumental Activities of Daily Living Scale (Lawton & Brody, 1969), the Functional 
Activities Questionnaire (FAQ; Pfeffer, Kurosaki, Harrah, Chance & Filos, 1982), and 
the Alzheimer Disease Activities of Daily Living International Scale (ADL-IS; Reisberg 
et al., 2001). However, there is as yet no IADL instrument that has been developed or 
validated for PD patients, other than a brief section in the Unified Parkinson’s Disease 
Rating Scale (UPDRS) which focuses primarily on motor impairments associated with 
PD (Jenkinson, Fitzpatrick & Peto, 1998).  To be useful in the current context, the IADL 
instrument selected needs to be relatively short and user-friendly so that it can be easily 
administered by non-specialist staff to the significant others of the patients suffering from 
PD.  
Current research at the Van der Veer Institute (VDV) has used Reisberg’s ADL-
IS (Reisberg et al., 2001), which is a 40-item questionnaire that identifies 13 ADL 
categories. Moreover, the ADL-IS was originally developed to detect sensitivity in the 
MCI range in AD. Table 2 describes the various categories and their individual items in
the ADL-IS measure. Each category has individual items ranging from a minimum of one 
item to a maximum of six items. In each of the 13 categories, the items range in order 
from the least difficult to the most challenging (Reisberg et al., 2001). A 5-point scale is 
used to score the items (see methods). Appendix 2 shows the Reisberg’s ADL-IS 
questionnaire. 
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Table 2
The Reisberg Alzheimer’s Disease Activities of Daily Living International Scale (ADL-
IS)
Domains Individual Items
Conversation Difficulty participating meaningfully in 
conversation, and Wordfinding difficulties
Recreation Problems operating Television/radio, and 
Difficulty recalling things watched on 
Television/movies
Self-Care Being reminded to clean clothes
Household Activities Problems placing house hold items, 
Difficulty doing house tasks, and Difficulty 
performing simple activities
General Activities Getting muddled to complete an activity, 
Difficulty continuing an activity, and 
Problems learning something new
Medication Difficulty monitoring simple medication 
regime, and Requiring close supervision 
for taking medications
Social Functioning Forgeting significant dates, Events, and 
Names
Telephone Difficulty remembering frequently dialled 
telephone number, and Problems recalling 
new numbers
Reading Difficulty reading newspaper, 
Concentration problems, Difficulty 
recalling materials read, and Reading 
several times
Organization Difficulty organising, Problems giving 
direction, Multitasking difficulties, 
Misplace personal belongings, and 
Difficulty completing forms 
Food Preparation Difficulty in preparing non-simple foods, 
Problems measuring correct quantity, 
Difficulty measuring the amount of 
seasoning, and Ingredients, and Difficulty 
Cooking variety of meals 
Travel Difficulty walking without getting lost, 
Overwhelm with new information, 
Concentrate on landmarks more, Difficulty 
map reading of new places, Problems 
touring unfamiliar places, and Difficulty
following map to a new place
Driving Difficulty driving between familiar routes
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An example of the value of the ADL-IS was observed in a recent study that 
revealed greater difficulties in both amnestic and non-amnestic MCI patients (Schmitter-
Edgecombe et al., 2009). A different ADL example comes from a study that sought to 
generate a brief set of items to screen MCI and early dementia (Li et al., 2006). Li et al. 
(2006) developed a brief 4-item instrument (personal belongings, finance, keeping 
appointments and reading) for this purpose was selected from the original 45-item 
ADCS-ADL inventory. Combined with a question concerning memory impairment, their 
brief instrument produced high sensitivity (86%) and specificity (85%) for detecting MCI 
and early AD. Another study conducted by Peres and colleagues (2008) indicated that 
four IADLs could predict risk of subsequent dementia. These four IADLs were 
telephone, transportation, medication and finances. These recent studies suggest that a 
truncated list of activities may be valid to screen current and future functional 
independence in the context of PD.
The Current Study
The identification of cognitive status in PD is essential to predict future cognitive decline, 
including development of PD dementia and severely reduced quality of life. It would be
particularly valuable to establish screening tools with high sensitivity and specificity to 
allow rapid assessment of cognitive status. These screening tools would help identify PD 
individuals that may need more comprehensive testing and suggest potential clinical 
management for PD-MCI and previously undiagnosed early PD-D cases. In summary, the 
general aim of the current study was to arrive at a relatively short list of IADL items, 
suitable for use in a clinical environment. We will re-examine the discriminant value of 
the MoCA and then, in particular, its value when combined with selected IADLs to 
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classify PD patients with generally normal cognition (PD-N), PD with mild cognitive 
impairment (PD-MCI) and PD with dementia (PD-D).  Extensive neuropsychological 
testing was done to classify the PD patients into PD-N, PD-MCI or PD-D. The diagnosis 
of PD-D was based on the Movement Disorders Society Task Force (Dubois et al., 2007; 
Emre et al., 2007), whereas for PD-MCI, two criteria were used. The first criterion is the 
current VDV standard; the second is an alterative based on a detailed evaluation of 12 
different neuropsychological criteria (Dalrymple-Alford et al., 2011). One MCI criterion 
required an impairment at 1.5 SD below the norms on two measures in at least one of 
four cognitive domains (1.5SD:2 one-domain); second required impairment at 1.5 SD 
below normative data in at least one measure but in two-domains (1.5SD:1 two-domains). 
Method
Participants
A convenience sample of 162 patients suffering from PD and 53 volunteer control 
subjects were recruited who were a part of a longitudinal study conducted at the VDV
Institute for Parkinson’s and Brain Research in Christchurch. Diagnosis of probable PD 
was made by Tim J Anderson, a movement disorders neurology specialist. UPDRS-III
(Gancher, 1997) with Hoehn and Yahr staging (Hoehn and Yahr, 1967) was used to 
assess motor function. General exclusion criteria included atypical parkinsonian disorder, 
other neurological or major medical conditions (e.g. head injury, stroke, early life 
disability), current psychiatric problems, duration of PD less than a year (to minimise 
misdiagnosis), and unable to use English fluently. Due to the nature of the study, 
participants were also excluded if assessment was not conducted on the Activities of 
Daily Living – International Scale (ADL-IS; Reisberg et al., 2001). A total of 56 patients 
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suffering from PD were excluded for the following reasons. Fifty PD patients were 
excluded because they did not undergo ADL assessment (involved in other studies or no 
significant other was available). Another four PD patients were excluded because their
duration of PD was <1 year (to avoid dementia with Lewy bodies). Two PD patients were 
excluded because of other psychiatric illness or poor English. The final inclusions of 106 
PD patients were classified on the basis of two criteria. When using the 1.5SD:2 (for one 
domain) criterion for PD-MCI, there were: 48 PD patients with normal cognition (PD-N);
34 PD patients with mild cognitive impairment (PD-MCI); and 24 PD patients with 
dementia (PD-D).When PD-MCI was classified using the 1.5SD:1 (for two domain) 
criterion, there were: 43 PD-N, 39 PD-MCI and 24 PD-D. Tables 3 and 4 summarise the
demographic and clinical variables across the three PD groups and controls for 1.5SD:2 
and 1.5SD:1 criteria respectively. All included patients underwent evaluation using the 
Reisberg IADL, but most (45 patients) did not undergo Functional Activities 
Questionnaire (FAQ) and Informant Report of Memory Problem (IRMP and these 
alternate ADL instruments are thus not considered further). One PD-D patient did not 
undergo Scales for Outcomes in Parkinson disease-Cognition (SCOPA-Cog) or
Alzheimer’s Disease Assessment Scale-Cognition (ADAS-Cog) assessment. 
Fifty-three control participants were community volunteers, contacted through
local advertisements. A total of 11 and 15 controls did not undergo the SCOPA-Cog and 
the Reisberg’s ADL-IS assessment respectively, but absence of ADL scores was not an 
exclusion for these participants. A total of three control participants were excluded due to 
abnormal MRI scans. Of the remaining 50 control participants, three were excluded due 
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Table 3
Demographic and clinical comparison of the three PD groups and Controls for 1.5SD:2 one-domain MCI criterion+
HC
(n = 47)
PD-N
(n = 48)
PD-MCI (1)
(n = 34)
PD-D
(n = 24)
ANOVA/Kruskal-
Wallis
Adjacent pairwise 
comparisons *
M/F 32/15 32/16 23/11 21/5
Age (y) 67.28
(9.25)
67.10 
(7.29)
71.71 (4.93) 72.88
(7.14)
F3,149 = 5.44, p < 0.01 HC = PD-N < PD-MCI = PD-D
Education (y) 13.72
(3.01)
13.09 
(2.72)
12.38 (2.90) 12.75 
(2.95)
F3,149 = 1.47, p = 0.22 NS
Premorbid IQ(WTAR) 112.40
(9.40)
113.27
(7.42)
108.44
(9.55)
107.54
(10.67)
F3,149 = 3.44, p < 0.05 HC = PD-N = PD-MCI = PD-D
Geriatric Depression 
Scale (15-item)
0.02
(0.15)
0.79
(1.62)
1.50 
(2.48)
3.38
(3.32)
F3,149 = 16.14, p < 0.001 HC = PD-N = PD-MCI < PD-D
Neuropsychiatric 
Inventory
N/A 3.13 
(5.48)
5.88 
(7.82)
10.04 
(8.04)
F2,103 = 8.08, p < 0.01 PD-N = PD-MCI < PD-D
Duration of symptoms 
(y)
N/A 5.23 
(3.86)
6.75 
(4.49)
12.16 
(7.88)
F2,103 = 14.42, p < 0.001 PD-N = PD-MCI < PD-D
Hoehn & Yahr Stage N/A 1.93
(0.63)
2.41
(0.78)
3.35
(0.75)
F2,101 = 31.75, p < 0.001 PD-N < PD-MCI < PD-D
UPDRS N/A 20.69
(10.34)
28.64
(14.43)
49.87
(17.50)
F2,101 = 36.42, p < 0.001 PD-N < PD-MCI < PD-D
Abbreviations: ANOVA = analysis of variance; HC = healthy age- and education-matched controls; NS = not significant; PD-D = patients with 
Parkinson disease with dementia; PD-MCI = patients with Parkinson disease with mild cognitive impairment; PD-N = patients with Parkinson 
disease with normal cognition; WTAR = Wechsler Test of Adult Reading; UPDRS = Unified Parkinson disease Rating Scale-Motor Score.
+ Values are mean (SD)
* p < 0.05 for post hoc test
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Table 4
Demographic and clinical comparison of the three PD groups and Controls for 1.5SD:1 two-domain MCI criterion+
HC
(n = 45)
PD-N 
(n = 43)
PD-MCI (2)
(n = 39)
PD-D 
(n = 24)
ANOVA/Kruskal-
Wallis
Adjacent pairwise 
comparisons *
M/F 28/17 31/12 24/15 21/3
Age (y) 67.07
(8.46)
67.81
(7.45)
70.33
(5.76)
72.86 
(7.14)
F3,147 = 4.08, p < 0.01 HC = PD-N = PD-MCI = PD-D
Education (y) 13.87
(3.00)
13.04
(2.67)
12.54
(2.95)
12.92
(2.90)
F3,147 = 1.59, p = 0.194 NS
Premorbid 
IQ(WTAR)
113.11
(8.92)
113.28
(8.04)
109.05
(8.86)
107.54
(10.67)
F3,147 = 3.53, p < 0.05 HC = PD-N = PD-MCI = PD-D
Geriatric 
Depression Scale 
(15-item)
0.02
(0.15)
0.54
(1.16)
1.69
(2.58)
3.36 
(3.32)
F3,147 = 17.71, p < 0.001 HC = PD-N < PD-MCI < PD-D
Neuropsychiatric 
Inventory
N/A 3.56
(6.98)
5.05
(6.25)
10.04 
(8.04)
F2,103 = 6.82, p < 0.01 PD-N = PD-MCI < PD-D
Duration of 
symptoms (y)
N/A 5.21
(4.03)
6.58
(4.27)
12.16 
(7.88)
F2,103 = 14.23, p < 0.001 PD-N = PD-MCI < PD-D
Hoehn & Yahr 
Stage
N/A 1.97
(0.66)
2.30
(0.77)
3.35
(0.75)
F2,101 = 28.21, p < 0.001 PD-N < PD-MCI < PD-D
UPDRS N/A 20.42
(10.75)
27.90
(13.70)
49.87
(17.50)
F2,101 = 35.92, p < 0.001 PD-N < PD-MCI < PD-D
Abbreviations: ANOVA = analysis of variance; HC = healthy age- and education-matched controls; NS = not significant; PD-D = patients with 
Parkinson disease with dementia; PD-MCI = patients with Parkinson disease with mild cognitive impairment; PD-N = patients with Parkinson 
disease with normal cognition; WTAR = Wechsler Test of Adult Reading; UPDRS = Unified Parkinson disease Rating Scale-Motor Score.
+ Values are mean (SD)
* p < 0.05 for post hoc test
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to being classified as MCI leaving 47 healthy controls for analysis at 1.5SD:2 criterion 
and five as MCI leaving 45 healthy controls for analysis at 1.5SD:1 criterion.
The study was approved by the Upper South Ethics Committee. Informed consent 
was provided by all participants with additional consent from a significant other when 
required.
Neuropsychological and Neuropsychiatric Assessment
An extensive battery of neuropsychological tests was given in two morning sessions by 
trained psychometricians at the VDV. Participants were tested while taking their regular 
medications. The neuropsychological tests were conducted with a fixed order that 
balanced verbal and nonverbal materials. Breaks were provided in both sessions to avoid 
fatigue. A separate interview was carried out with a significant other when assessing
activities of daily living and functional status. In additional to conceptual and statistical 
analyses, my role was to carry out the separate interview with the significant other in 
some cases (10-15 assessments).
The four cognitive domains proposed for PD-D by the Movement Disorders 
Society Task Force (Dubois et al., 2007) were used. Executive function was assessed 
using the Stroop Interference Test, Letter Fluency, Action Fluency, Category Fluency, 
Category Switching, and Trails Making Test Part B (TMT-B; Delis, Kaplan, & Kramer, 
2001; Piatt, Fields, Paolo, & Troster, 1999; Reitan, 1958). Attention, working memory 
and processing speed was examined by Digit Span (Forward plus Backward), Digit 
Ordering Test, Test of Everyday Attention-Map Search (TEA-Map Search), Stroop Word 
and Colour Test and TMT Part A (TMT-A; Delis, Kaplan, & Kramer, 2001; Reitan, 
1958; Robertson, Ward, Ridgeway, & Nimmo-Smith, 1996; Wechsler, 1997; Werheid, 
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Hoppe, Thone, Muller, Mungersdorf, & von Cramon, 2002). Visuospatial and 
visuoperception skills were assessed using the Judgement of Line Orientation (JOL), the 
fragmented letter task of the Visual Object and Space Perception Battery (VOS) and copy 
of the Rey-Osterrieth Complex Figure (ROCF; Benton, Hannay, & Varney, 1975; Meyers 
& Meyers, 1995; Warrington & James, 1991). Learning and memory was assessed using 
the free recall, short and long delay recall components of the California Verbal Learning 
Test-2 short form (CVLT-II)) and the immediate (i.e., “short”) and delayed recall 
components of ROCF (Delis, Kramer, Kaplan, & Ober, 2002; Meyers & Meyers, 1995); 
for each memory test, either but not both short and long delay could contribute to an 
“impairment”.
The diagnosis of PD-D was based on the criteria established by the Movement 
Disorder Society Task Force (Dubois et al., 2007; Emre et al., 2007), which is 
“significant impairment” (in practice, -2.0 SD below normative data) in at least one 
measure in two cognitive domains, supporting evidence from two dementia assessment 
tests (Dementia Rating Scale-2 (DRS-2), Alzheimer’s Disease Assessment Scale-
Cognition (ADAS-Cog; Harvey et al., 2009; Jurica et al., 2001), together with evidence
of impairment relevant to everyday function from a significant other (ADL-IS, Reisberg 
et al., 2001); Clinical Dementia Rating (CDR, Morris, 1993), and Global Deterioration 
Scale (Reisberg, Ferris, de Leon, & Crook, 1988). The diagnosis of PD-MCI was based 
on two criteria: 1.5SD:2 and 1.5SD:1 MCI criteria. No PD-MCI participants met the 
criterion for dementia (i.e., no significant impairment in everyday function). PD-N 
participants did not meet the relevant criteria for PD-MCI.
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The Montreal Cognitive Assessment (MoCA; Nasreddine et al., 2005) was 
administered to all the participants at the start of the second session. As per standard, 
each item in the seven MoCA domains was scored either a 0 or 1, except for Serial 
seven’s where a score of up to three was awarded. An additional score was given if 
education was < 12 years. A higher score represents more intact cognition (maximum = 
30). For participants tested twice on the MoCA (n = 34), the score that was obtained at 
the same time as other neuropsychological and neuropsychiatric measures was taken. The 
MoCA was scored independently. That is, the MoCA was not used to classify 
participants into their cognitive status groups. The S-MMSE (Folstein et al., 1975; 
Malloy & Standish, 1997) was also administered to all the participants. Neuropsychiatric 
status for all the participants was evaluated using the Neuropsychiatric Inventory 
(Cummings, Mega, Gray, Rosenberg-Thompson, Carusi, & Gornbein, 1994) and the 15-
item Geriatric Depression Scale (Yesavage, Brink, Rose, Lum, Huang, Adey, & Leirer,
1982). 
The ADL-IS (Reisberg et al., 2001, Appendix 2) was used to assess everyday 
functional status. Significant impairment in IADLs is necessary for the diagnosis of 
dementia. The ADL-IS ratings were obtained from a reliable informant such as a spouse, 
other family member, or close friend. The 40 items were scored on a 5-point scale that 
indicated ‘never has difficulty with the activity’ scored as 0, ‘sometimes has difficulty 
with the activity’ scored as 1, ‘often has difficulty with the activity’ scored as 2, ‘always 
has difficulty with the activity’ scored as 3, and ‘activity is no longer performed’ scored
as 4. If an activity was “never performed” or if the performance on the activity was “not 
known”, these items were not scored. To avoid the influence of missing items, the total 
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ADL-IS score was obtained by the usual practice of dividing the mean scores for items 
with values 0 to 4 by the number of items with scores between 0 and 4. For the purpose 
of this study, the total ADL-IS score, the 13 category scores and then the individual item 
scores on each of the 40 items for all the PD participants were analysed. No cut-off score 
for the ADL (by itself) was used to establish the three PD groups, but the total and 
individual item scores were evaluated independently by ROC analysis. 
Statistical Analyses
Demographic, neuropsychological and neuropsychiatric measures were examined using 
one way analysis of variance (ANOVA) or Kruskal-Wallis tests (for nonparametric data), 
with post hoc tests (Newman-Keuls or Conover; MedCalc) to examine differences across 
the three PD groups and controls.
To screen PD patients accurately, especially PD-MCI or PD-D, one obvious 
option would be to use both the MoCA and full ADL-IS measure. However, a primary
aim of this study was to have the MoCA along with a brief set of ADL measures that 
might be able to screen for a diagnosis relevant to the group a PD patient falls rather than 
administering the full 40 items of the ADL-IS measure. Therefore, logistic regression was 
performed using both the MoCA along with four or five ADL items, which is a suitable
number of variables given the need to have n = 10 to 15 subject per variable for logistic 
regression. To determine the cut-off points for the MoCA and ADL-IS measures, receiver 
operating characteristic (ROC) curve analysis was performed in MedCalc version 
11.3.1.0 (www.medcalc.be) between PD-D vs PD-MCI, and PD-MCI vs PD-N.
A series of steps were followed for variable reduction in order to obtain the five 
ADL items that were combined with the MoCA for the analysis between PD-D vs PD-
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MCI, and PD-MCI vs PD-N. These series of steps were 1) Basic ADL items and ADL 
items that are likely to be influenced primarily by motor symptoms due to PD were 
excluded (see Results). 2) Some of the ADL items had missing data. Therefore, ADL 
items with 5% of missing data in any PD group were eliminated. 3) If one category had 
more than two items, then the two items that were judged to be closer on the basis of 
clinical relevance to dementia were kept. After these three steps, eight ADL items (two 
individual items from two different categories and six items from three other categories) 
were retained (see Results). 4) These remaining ADL items were analysed using the 
Statistical Package for Social Sciences (SPSS) for tolerance to multi-collinearity values. 
All eight ADL items had tolerance of above 0.2 between PD-D vs PD-MCI, and PD-MCI
vs PD-N (http://faculty.chass.ncsu.edu/garson/PA765/regress.htm). 5) For those 
categories with two items, any items with no missing data were kept. If both items had 
either missing data or no missing data, then one item was randomly chosen. Finally, five 
categories remained each with a single item (see Results). 
The MoCA was initially analysed alone between PD-D vs PD-MCI, and PD-MCI
vs PD-N. Then logistic regression modelling was used to evaluate the ability of both the 
MoCA combined with ADL items as independent predictors of PD-D vs PD-MCI, and 
PD-MCI vs PD-N. Among the logistic regression analysed, firstly, the MoCA was 
analysed with the total ADL-IS score. Secondly, the MoCA along with the five selected 
ADL items were analysed using a stepwise regression that was dependent on the 
significant value (p < 0.05 for any ADL item) and the highest odds ratio to create a 
composite screening instrument. Subsequently, three separate logistic regressions were 
analysed: 1) the MoCA with Muddled and Complex Medication ADL-IS items, 2) the 
Vineetha Uthamaputhiran
68266341
21
MoCA with Complex Medication alone, and 3) the MoCA with an average of four other 
ADL items for use in the event that Complex Medication was absent or excluded (one 
ADL variable based on an average score of Muddled, Get Lost, Confusion and 
Multitasking). The outcome (composite) score derived from the regression equation for 
each individual was used to generate a ROC curve analysis to determine optimal 
screening values, optimal diagnostic values and maximum accuracy values (Youden 
Index). The logistic regression gave values for the standardised beta coefficients, and a 
constant, reflected by the basic regression equation, Yroc = a0 + • 1 X1 + • 2 X2 + … + • k
Xk, where Yroc is a ROC cut-off value, a0 is the constant, •1, • 2, …, • k are beta coefficients, 
and X1, X2, …, Xk are independent variables. These standardised beta coefficients, and 
constants were substituted in the regression equation to obtain the logit(p) value for Yroc
which was then transformed to p (logit(p) = a0 + • 1 X1 + • 2 X2 + … + • k Xk ).  The logit 
transformation table is inserted in Appendix 3. The equation derived cut-offs for optimal 
screening value, optimal diagnostic values or maximum accuracy values. When the value 
obtained by the logistic regression is greater than the p cut-off value obtained for optimal
screening value, optimal diagnostic value or maximum accuracy values, then that score 
was treated as being in the disease group. If the value obtained by logistic regression was 
less than or equal to the p cut-off value, then the score was regarded to be in the non-
disease group for pairwise comparisons between PD-D vs PD-MCI, and PD-MCI vs PD-
N.
Following a design suggested by Steenland, Auman, Patel, Bartell, Goldstein, 
Levey, & Lah (2008), grids were constructed for the three separate logistic regressions: 
the MoCA with Muddled and Complex Medication ADL-IS items, MoCA with Complex 
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Medication alone, and MoCA with an average of the four other ADL items (excluding 
Complex Medication). Each grid was formed for optimal screen values, optimal 
diagnostic values and maximum accuracy values for both the criteria (1.5SD:2 and 
1.5SD:1) for PD-D, PD-MCI and PD-N. 
Results
1.5SD:2 one-domain MCI criterion
As stated earlier, the diagnosis of PD-MCI can be based on two criteria (Dalrymple-
Alford et al., 2011). The 1.5SD:2 standard VDV criterion is when 1.5 SD below 
normative data is obtained on two measures in at least one of four cognitive domains for 
the diagnosis of PD-MCI. The main analysis is performed using this criterion. The 
second is an alterative criterion which was also analysed and the main results are 
presented in the next section.
Demographics
The mean age of the two cognitively normal groups was younger when compared to both 
PD-MCI and PD-D, whereas there were no group differences among the four groups for 
education (Table 3). Premorbid IQ estimates were similar across the four groups. Age 
showed a moderate correlation with ADL-IS and the MoCA (Spearman’s r = 0.28, p < 
0.01, and r = -0.41, p < 0.001 respectively; n = 106). No correlations were found between 
education with either ADL-IS or MoCA (r = 0.01 and r = 0.06 respectively, n = 106). For 
the Geriatric Depression Scale, higher scores were evident for the PD-D group when
compared against the other three groups. Longer disease duration along with severe 
motor impairments was seen in patients with PD-D. The other two PD groups had similar 
duration of PD symptoms. The patients with PD-MCI performed significantly worse than 
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PD-N for the measures that examined motor impairments. Neuropsychiatric Inventory 
scores were lower in both PD-N and PD-MCI as opposed to the PD-D group. 
Cognitive Assessments
The scores on the MoCA, MMSE and the SCOPA-COG were poorest for the PD-D 
group when compared against all the other groups, followed by the PD-MCI group,
which was lower than the PD-N and control groups (Table 5). These differences were 
maintained when age and education were added as covariates (all F > 42.00, p < 0.001).
On the SCOPA-COG, there was a significant but small difference between the control 
and PD-N groups, but these groups did not differ in their MoCA or MMSE scores. These 
findings are consistent with a recent study at the VDV (Dalrymple-Alford et al., 2011).
As expected, poorer (i.e., higher) scores were obtained by the PD-D group than all 
the other groups on the functional status measures such as ADL-IS, CDR and GDS. The 
PD-MCI group obtained higher scores than the PD-N and control groups on the 
functional status measures. The control group scored the lowest on the ADL-IS measure, 
which was significantly lower when compared against the PD-N group, but both these 
groups performed similarly on the CDR and GDS. The PD-D group also performed 
worse on the dementia assessment measures (ADAS-COG and DRS-2) than all other 
groups. This was followed by the PD-MCI group, and then the PD-N group, which was 
similar to controls.
The PD-D group performed worse compared to the other three groups on all four 
neuropsychological domains. The PD-MCI group also obtained worse scores on all of the 
four neuropsychological domains compared to the PD-N and control groups. In turn, the 
PD-N group performed worse compared to the control group on the neuropsychological 
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Table 5
Mental status tests, functional status, dementia assessment and neuropsychological domains for the three PD groups and Controls for 1.5SD:2 
one-domain MCI criterion +
HC
(n = 47)
PD-N 
(n = 48)
PD-MCI (1)
(n = 34)
PD-D 
(n = 24)
ANOVA/Kruskal-
Wallis
Adjacent pairwise 
comparisons *
Mental status tests
MoCA 27.21
(1.89)
26.59
(2.00)
23.35
(2.84)
17.29
(4.05)
F3,149 = 95.91, p < 0.001 HC = PD-N > PD-MCI > PD-D
MMSE-Sevens 28.57
(1.57)
28.19
(1.67)
25.88
(2.35)
22.91
(2.84)
F3,149 = 50.84, p < 0.001 HC = PD-N > PD-MCI > PD-D
MMSE-World 29.04
(1.04)
28.81
(1.23)
27.21
(1.75)
24.13
(3.07)
F3,149 = 51.76, p < 0.001 HC = PD-N > PD-MCI > PD-D
SCOPA-COG 33.89
(4.26)
31.65
(4.06)
25.88
(4.33)
15.35
(4.98)
F3,137 = 101.53, p < 0.001 HC > PD-N > PD-MCI > PD-D
Functional status
ADL-IS 0.19
(0.22)
0.42
(0.54)
0.69
(0.49)
1.99
(0.45)
F3,133 = 83.39, p < 0.001 HC < PD-N < PD-MCI < PD-D
CDR-Box 0.03
(0.12)
0.49
(1.09)
1.43
(1.09)
7.27
(2.54)
F3,133 = 164.11, p < 0.001 HC = PD-N < PD-MCI < PD-D
GDS 1.00
(0.00)
1.17
(0.38)
2.18
(0.88)
4.21
(0.83)
F3,131 = 166.00, p < 0.001 HC = PD-N < PD-MCI < PD-D
Dementia assessment
ADAS-COG 4.86
(2.20)
5.89
(2.26)
10.08
(3.48)
21.45
(8.09)
F3,137 = 95.02, p < 0.001 HC = PD-N < PD-MCI < PD-D
DRS–2 (AEMSS) 13.06
(2.29)
12.40
(1.89)
10.00
(1.83)
4.96
(2.68)
F3,137 = 83.95, p < 0.001 HC = PD-N > PD-MCI > PD-D
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Neuropsychological domains
Executive Function 0.83
(0.52)
0.35
(0.66)
-0.66
(0.70)
-1.98
(0.54)
F3, 149 = 130.38, p < 0.001 HC > PD-N > PD-MCI > PD-D
Attention, working memory, 
and processing speed
0.36
(0.45)
-0.06
(0.41)
-0.90
(0.45)
-1.89
(0.55)
F3, 149 = 150.87, p < 0.001 HC > PD-N > PD-MCI > PD-D
Learning and Memory 0.91
(0.78)
0.16
(0.74)
-0.75
(0.74)
-1.77
(0.65)
F3, 149 = 80.17, p < 0.001 HC > PD-N > PD-MCI > PD-D
Visuospatial/visuoperceptual 0.53
(0.45)
0.36
(0.45)
-0.26
(0.68)
-1.23
(0.80)
F3,149 = 59.51, p < 0.001 HC = PD-N > PD-MCI > PD-D
Aggregate mean score 
across the 4 domains
0.66
(0.37)
0.20
(0.42)
-0.64
(0.40)
-1.72
(0.51)
F3,149 = 200.90, p < 0.001 HC > PD-N > PD-MCI > PD-D
Abbreviations: ADAS-COG = Alzheimer’s Disease Assessment Scale-Cognition; ADL-IS = Activities of Daily Living-International Scale; ANOVA = 
analysis of variance; CDR = Clinical Dementia Rating; DRS-2 = Dementia Rating Scale-2, using age-and education-adjusted standard scores; GDS = Global 
Deterioration Scale; HC = healthy age- and education-matched controls; MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive Assessment; 
PD-D = patients with Parkinson disease with dementia; PD-MCI = patients with Parkinson disease with mild cognitive impairment; PD-N = patients with 
Parkinson disease with normal cognition; SCOPA-COG = Scales for Outcomes in Parkinson disease-Cognition.
+ Values are mean (SD)
* p < 0.05 for post hoc test
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domains, with the exception of visuospatial/visuoperception domain, but their mean 
scores did not suggest impaired performance with regard to normative data.
Activities of Daily Living
Table 6 shows the means of 13 categories and 40 individual items of the ADL-IS
measure. The standard way of scoring for total ADL-IS score was obtained by dividing 
the average scores for items with values 0 to 4 by the number of items with scores 
between 0 and 4. A maximum score of 4 represents that the participant no longer 
performs activities which they were formerly engaged in, and a minimum score of 0 
represents that the participant never experiences problems in performing activity of daily 
living.  The means on the total ADL-IS scores indicate that, overall, patients in the PD-D 
group were impaired in performing the activities of daily living. The PD-MCI patients 
performed significantly different from PD-N on the total ADL-IS scores.
Firstly, analysing the means in all 13 categories, the means for PD-D were higher 
than the other two PD groups. The means for PD-MCI were significantly greater than 
PD-N in household activities, general activities, organisation, and travel, whereas it was 
similar to PD-N in the remaining nine categories. Secondly, analysing the 40 individual 
items on the ADL-IS among the 13 categories, the PD-D patients performed worse on all 
the individual items except for an individual item under the travel category where the 
patients in the PD-D group performed similar to the other two PD groups. The patients in 
PD-MCI group performed significantly worse than PD-N on nine of the individual items 
from a total of 40 ADL-IS items. For the remaining individual items, the PD-MCI group 
performed similarly to the PD-N group.  
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Table 6
Means and Standard Deviations for the 40 ADL-IS Individual Items for the three PD groups for 1.5SD:2 one-domain MCI 
criterion +
PD-N 
(n = 48)
PD-MCI (1)
(n = 34)
PD-D 
(n = 24)
ANOVA/Kruskal-Wallis Adjacent pairwise 
comparisons *
Total ADL-IS 0.42
(0.54)
0.69
(0.49)
1.99
(0.45)
F2,103 = 80.81, p < 0.001 PD-N < PD-MCI < PD-D
Conversation
Converse 0.38
(0.67)
0.56
(0.66)
1.33
(0.82)
F2,103 = 15.28, p < 0.001 PD-N = PD-MCI < PD-D
Wordfinding 0.38
(0.73)
0.35
(0.54)
1.17
(0.98)
F2,102 = 10.63, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.38
(0.65)
0.46
(0.47)
1.25
(0.81)
F2,103 = 16.31, p < 0.001 PD-N = PD-MCI < PD-D
Recreation
Operating TV 0.17
(0.56)
0.36
(0.65)
1.46
(1.14)
F2,100 = 23.31, p < 0.001 PD-N = PD-MCI < PD-D
Recalling TV 0.27
(0.68)
0.47
(0.61)
1.18
(0.85)
F2,101 = 13.02, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.22
(0.51)
0.43
(0.52)
1.33
(0.83)
F2,102 = 27.13, p < 0.001 PD-N = PD-MCI < PD-D
Self-Care
Cleaning clothes 0.26
(0.61)
0.42
(0.83)
1.33
(1.49)
F2,101 = 10.80, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.26
(0.61)
0.42
(0.83)
1.33
(1.49)
F2,101 = 10.80, p < 0.001 PD-N = PD-MCI < PD-D
Household Activities
Placing Items 0.29
(0.65)
0.38
(0.61)
1.25
(1.26)
F2,101 = 11.85, p < 0.001 PD-N = PD-MCI < PD-D
Household Tasks 0.23
(0.52)
0.41
(0.86)
1.78
(1.24)
F2,102 = 28.80, p < 0.001 PD-N = PD-MCI < PD-D
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Confusion 0.43
(0.93)
0.97
(0.83)
1.83
(1.05)
F2,102 = 18.36, p < 0.001 PD-N < PD-MCI < PD-D
Complex Items 0.48
(0.90)
0.94
(1.12)
2.38
(0.97)
F2,102 = 29.82, p < 0.001 PD-N < PD-MCI < PD-D
Average for the Category 0.35
(0.59)
0.68
(0.61)
1.81
(0.77)
F2,103 = 41.73, p < 0.001 PD-N < PD-MCI < PD-D
General Activities
Muddled 0.21
(0.50)
0.62
(1.04)
1.54
(1.10)
F2,103 = 19.32, p < 0.001 PD-N < PD-MCI < PD-D
Preserve 0.27
(0.54)
0.44
(0.70)
1.67
(1.05)
F2,103 = 30.96, p < 0.001 PD-N = PD-MCI < PD-D
Learning 0.52
(0.95)
0.94
(1.09)
2.17
(1.01)
F2,102 = 21.61, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.33
(0.55)
0.66
(0.66)
1.79
(0.79)
F2,103 = 41.56, p < 0.001 PD-N < PD-MCI < PD-D
Medication
Simple Medication 0.60
(1.05)
0.68
(1.12)
2.39
(1.16)
F2,102 = 23.15, p < 0.001 PD-N = PD-MCI < PD-D
Complex Medication 0.42
(0.90)
0.38
(0.82)
2.17
(1.24)
F2,103 = 31.330, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.51
(0.88)
0.53
(0.93)
2.25
(1.11)
F2,103 = 30.60, p < 0.001 PD-N = PD-MCI < PD-D
Social Functioning
Forget Significant Others 0.11
(0.38)
0.10
(0.31)
1.19
(0.98)
F2,92 = 31.07, p < 0.001 PD-N = PD-MCI < PD-D
Forget Events 0.25
(0.60)
0.31
(0.54)
1.42
(0.88)
F2,101 = 27.89, p < 0.001 PD-N = PD-MCI < PD-D
Forget Names 0.65
(0.82)
0.88
(0.77)
1.57
(0.95)
F2,100 = 9.27, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.35
(0.52)
0.49
(0.48)
1.39
(0.78)
F2,103 = 27.22, p < 0.001 PD-N = PD-MCI < PD-D
Telephone
Remember Frequent 
Numbers
0.71
(1.17)
0.68
(0.98)
1.96
(1.19)
F2,92 = 11.19, p < 0.001 PD-N = PD-MCI < PD-D
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Recall New Numbers 0.78
(0.99)
1.41
(1.18)
2.41
(1.10)
F2,89 = 16.38, p < 0.001 PD-N < PD-MCI < PD-D
Average for the Category 0.70
(0.85)
1.02
(1.00)
2.13
(1.00)
F2,99 = 18.47, p < 0.001 PD-N = PD-MCI < PD-D
Reading
Newspaper 0.29
(0.76)
0.59
(1.23)
1.40
(1.39)
F2,96 = 7.32, p < 0.01 PD-N = PD-MCI < PD-D
Concentration 0.42
(0.85)
0.63
(0.91)
1.64
(1.29)
F2,99 = 12.14, p < 0.001 PD-N = PD-MCI < PD-D
Recall 0.13
(0.34)
0.41
(0.82)
2.00
(1.26)
F2,91 = 41.93, p < 0.001 PD-N = PD-MCI < PD-D
Learning 0.27
(0.54)
0.64
(0.91)
1.62
(1.32)
F2,90 = 16.59, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.22
(0.51)
0.43
(0.52)
1.67
(0.98)
F2, 102 = 31.94, p < 0.001 PD-N = PD-MCI < PD-D
Organisation
Aviod 0.35
(0.79)
0.53
(0.75)
1.71
(1.20)
F2, 103 = 19.92, p < 0.001 PD-N = PD-MCI < PD-D
Directions 0.45
(0.72)
0.77
(0.99)
1.70
(0.97)
F2, 101 = 16.01, p < 0.001 PD-N = PD-MCI < PD-D
Multitasking 0.96
(1.04)
1.46
(1.12)
2.21
(1.02)
F2, 101 = 11.062, p < 0.001 PD-N < PD-MCI < PD-D
Misplace 0.90
(0.95)
1.00
(0.87)
2.04
(0.75)
F2, 102 = 14.61, p < 0.001 PD-N = PD-MCI < PD-D
Forms 0.43
(0.68)
0.85
(0.94)
2.08
(1.44)
F2, 101 = 22.82, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.61
(0.62)
0.90
(0.65)
1.95
(0.70)
F2, 103 = 35.31, p < 0.001 PD-N < PD-MCI < PD-D
Food Preparation
Non Simple 0.33
(0.77)
0.29
(0.69)
3.05
(1.28)
F2,94 = 78.71,  p < 0.001 PD-N = PD-MCI < PD-D
Quantity 0.39
(0.89)
0.16
(0.37)
3.14
(1.35)
F2,93 = 82.95, p < 0.001 PD-N = PD-MCI < PD-D
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Seasoning 0.39
(0.99)
0.18
(0.77)
3.00
(1.62)
F2,89 = 46.89, p < 0.001 PD-N = PD-MCI < PD-D
Ingredients 0.34
(1.03)
0.39
(0.92)
3.32
(1.29)
F2,88 = 58.54, p < 0.001 PD-N = PD-MCI < PD-D
Variation 0.53
(1.18)
0.89
(1.34)
3.45
(1.10)
F2, 84 = 41.13, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.44
(0.95)
0.39
(0.61)
3.15
(1.14)
F2, 95 = 74.98, p < 0.001 PD-N = PD-MCI < PD-D
Travel
Get Lost 0.23
(0.83)
0.41
(1.05)
0.88
(1.26)
F2,103 = 3.28, p < 0.05 PD-N = PD-MCI = PD-D
Overwhelm 0.45
(0.83)
0.94
(1.05)
1.58
(1.28)
F2,100 = 10.05, p < 0.001 PD-N < PD-MCI < PD-D
Landmarks 0.60
(1.17)
0.94
(1.44)
2.14
(1.62)
F2,96 = 9.49, p < 0.001 PD-N = PD-MCI < PD-D
Map Reading 0.43
(0.85)
1.03
(1.24)
2.48
(1.44)
F2,95 = 24.23, p < 0.001 PD-N < PD-MCI < PD-D
Touring Unfamiliar Places 0.68
(1.13)
1.84
(1.55)
3.78
(0.42)
F2,92 = 51.30, p < 0.001 PD-N < PD-MCI < PD-D
Map Follow 0.38
(0.77)
1.10
(1.35)
2.68
(1.52)
F2,96 = 29.57, p < 0.001 PD-N < PD-MCI < PD-D
Average for the Category 0.48
(0.78)
1.00
(0.97)
2.23
(0.69)
F2,103 = 35.52, p < 0.001 PD-N < PD-MCI < PD-D
Driving
Familiar Route 0.42
(1.08)
0.94
(1.52)
2.44
(1.85)
F2,99 = 15.21, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.42
(1.08)
0.94
(1.52)
2.44
(1.85)
F2,99 = 15.21, p < 0.001 PD-N = PD-MCI < PD-D
Abbreviations: ADL-IS = Activities of Daily Living-International Scale; ANOVA = analysis of variance; PD-D = patients with Parkinson disease with 
dementia; PD-MCI = patients with Parkinson disease with mild cognitive impairment; PD-N = patients with Parkinson disease with normal cognition.
+ Values are mean (SD)
* p < 0.05 for post hoc test
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A number of variables were excluded in order to obtain the five ADL items that 
were combined with the MoCA for the analysis between PD-D vs PD-MCI, and PD-MCI
vs PD-N. Table 7 shows the number of patients who received a score from 0 to 4 on the 
40 ADL-IS items and reasons for exclusions. Firstly, seven items were excluded because 
motor symptoms of PD were thought to influence these activities of daily living items. 
These seven items were difficulty participating in a conversation meaningfully, difficulty 
finding a desired TV or radio channel, trouble putting household items in the right places, 
being physically capable to do household tasks but still needs help from other, difficulty 
preparing foods that require more than minimal cooking, using landmarks and signposts 
more when walking or hiking, and difficulty driving between familiar spots without 
preparation. One ADL item, being reminded to clean clothes, was excluded because it 
was a basic ADL item. Secondly, 21 items were excluded because these items had 5% of 
missing data in any group. Finally, if one category had more than two items, then the two 
items that were closer on the basis of relevance to dementia were kept. After all the 
exclusions, a total of eight IADL items (Confusion, Complex Items, Muddled, Preserve, 
Complex Medication, Get Lost, Multitasking and Forms) were retained.
The remaining eight IADL items after all the exclusion were analysed for 
tolerance values (performed in SPSS). Tolerance values for the eight IADL items are
listed on Table 8. For all eight IADL items, the tolerance was above 0.20
(http://faculty.chass.ncsu.edu/garson/PA765/regress.htm) suggesting that multi-
collinearity was not important across those variables. The tolerance for PD-D vs PD-MCI 
for the eight IADLs ranged from a minimum of 0.35 to a maximum of 0.89 whereas the 
tolerance for PD-MCI vs PD-N ranged from a minimum of 0.42 to a maximum of 0.76.
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Table 7
Number of patients who scored from 0 to 4 on the 40 ADL-IS items and the reasons for the elimination of ADL-IS 
items for 1.5SD:2 one-domain MCI criterion
PD-N 
(n = 48)
PD-MCI (1)
(n = 34)
PD-D 
(n = 24)
Reasons for Elimination
Conversation
Converse 48 34 24 Influenced by PD Motor symptoms 
Wordfinding 48 34 23 5% missing data in PDD
Recreation
Operating TV 48 33 22 Influenced by PD Motor symptoms 
Recalling TV 48 34 22 5% missing data in PDD
Self-Care
Cleaning clothes 47 33 24 Basic IADL
Household Activities
Placing Items 48 32 24 Influenced by PD Motor symptoms 
Household Tasks 48 34 23 Influenced by PD Motor symptoms 
Confusion 47 34 24
Complex Items 48 33 24
General Activities
Muddled 48 34 24
Preserve 48 34 24
Learning 48 33 24 Less relevant to PD, especially PD-D when 
compared to other two items in the same 
category
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Medication
Simple Medication 48 34 23 5% missing data in PD-D
Complex Medication 48 34 24
Social Functioning
Forget Significant 
Others
45 29 21 5% missing data in PD-N, PD-MCI, and PD-D
Forget Events 48 32 24 5% missing data in PD-MCI
Forget Names 46 34 23 5% missing data in PD-N and PD-D
Telephone
Remember Frequent 
Numbers
41 31 23 5% missing data in PD-N, PD-MCI, and PD-D
Recall New Numbers 41 29 22 5% missing data in PD-N, PD-MCI, and PD-D
Reading
Newspaper 45 34 20 5% missing data in PD-N and PD-D
Concentration 48 32 22 5% missing data in PD-MCI and PD-D
Recall 45 29 20 5% missing data in PD-N, PD-MCI, and PD-D
Learning 44 28 21 5% missing data in PD-N, PD-MCI, and PD-D
Organisation
Aviod 48 34 24 Less relevant to PD, especially PD-D when 
compared to other two items in the same 
category
Directions 47 34 23 5% missing data in PD-D
Multitasking 47 33 24
Misplace 48 33 24 Less relevant to PD, especially PD-D when 
compared to other two items in the same 
category
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Forms 47 33 24
Food Preparation
Non Simple 45 31 21 Influenced by PD Motor symptoms 
Quantity 44 31 21 5% missing data in PD-N, PD-MCI, and PD-D
Seasoning 44 28 20 5% missing data in PD-N, PD-MCI, and PD-D
Ingredients 44 28 19 5% missing data in PD-N, PD-MCI, and PD-D
Variation 40 27 20 5% missing data in PD-N, PD-MCI, and PD-D
Travel
Get Lost 48 34 24
Overwhelm 47 32 24 5% missing data in PD-MCI
Landmarks 47 31 21 Influenced by PD Motor symptoms 
Map Reading 47 30 21 5% missing data in PD-MCI and PD-D
Touring Unfamiliar 
Places
41 31 23 5% missing data in PD-N, PD-MCI, and PD-D
Map Follow 47 30 22 5% missing data in PD-MCI and PD-D
Driving
Familiar Route 45 34 23 Influenced by PD Motor symptoms 
Abbreviations: ADL-IS = Activities of Daily Living-International Scale; PD-D = patients with Parkinson disease with 
dementia; PD-MCI = patients with Parkinson disease with mild cognitive impairment; PD-N = patients with 
Parkinson disease with normal cognition.
Vineetha Uthamaputhiran
68266341
35
Table 8
Tolerance values for the eight ADL-IS Individual Items for 1.5SD:2 one-domain 
MCI criterion
PD-MCI vs PD-N
(n = 82)
PD-D vs PD-MCI
(n = 58)
Household Activities
Confusion 0.419 0.531
Complex Items 0.498 0.354
General Activities
Muddled 0.632 0.527
Preserve 0.567 0.415
Medication
Complex Medication 0.667 0.682
Travel
Get Lost 0.759 0.887
Organisation
Multitasking 0.509 0.645
Forms 0.657 0.534
Abbreviations: ADL-IS = Activities of Daily Living-International Scale; PD-D = patients with Parkinson 
disease with dementia; PD-MCI = patients with Parkinson disease with mild cognitive impairment; PD-N = 
patients with Parkinson disease with normal cognition.
Analysis of MoCA with Activities of Daily Living
As our aim for a logistic regression was to arrive with a maximum of five to six variables 
including the MoCA, the eight IADL items were further reduced. Categories with a 
single IADL item were kept (Complex Medication and Getting Lost during travel). One 
of each pair of the remaining three items was randomly chosen resulting in the inclusion 
of Multitasking, Muddled and Confusion from three different categories. 
PD-MCI vs PD-N. Table 9 indicates the diagnostic performance of the MoCA, total 
ADL-IS, and the MoCA when combined with total ADL-IS between PD-MCI and PD-N 
for the standard VDV criteria (1.5SD:2). This table also shows 3 standard cut-off options 
for each test. ROC curve diagnostics are provided for 1) optimal screening values – the
lowest value with >80% for both sensitivity (detection of true positive cases) and 
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negative predictive value (NPV; probability of an accurate negative test), 2) optimal 
diagnostic values – the highest values with >80% for both specificity (detection of true 
negatives) and positive predictive value (PPV; probability of an accurate positive test), 
and 3) maximum accuracy values (Youden Index) which is the highest combination of 
sensitivity and specificity. The primary interest for a mental status test is the screening 
cut-off whereas the diagnostic cut-off is often used as a supplementary measure for other 
diagnostic tests. 
When discriminating patients with PD-MCI from patients with PD-N, high AUC 
was obtained for the MoCA, and MoCA with total ADL-IS (Table 9). The AUCs for the 
MoCA, and MoCA with total ADL-IS were significantly better than the total ADL-IS 
measure by itself (AUC difference of 17%, p = 0.022, and AUC difference of 18%, p = 
0.007 respectively).
Further analysis using logistic regression was done to predict group membership 
based on the MoCA and the final five ADL-IS items. None of the ADL-IS items 
significantly contributed to the logistic regression apart from Complex Medication ADL-
IS item (p < 0.05). However, when MoCA and only Complex Medication item was 
analysed in a logistic regression, the Complex Medication ADL-IS item was not itself 
significant and the AUC for MoCA with Complex Medication (85%) was similar to the 
AUC obtained by the MoCA by itself (85%).  Therefore, to identify PD-MCI from PD-N
patients, the data suggests that the MoCA is a sufficiently suitable screening measure and 
is not improved by adding any ADL items, despite there being some significant 
differences between PD-MCI and PD-N on some ADL items (Table 6).
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Table 9
Diagnostic performance of the MoCA, total ADL-IS and the MoCA along with the total ADL-IS between PD-N and PD-MCI for 1.5SD:2 one-domain MCI 
criterione
Optimal Screen Valuesa Optimal Diagnostic Valuesb Maximum Accuracy (Youden Index)c
Test (AUC, 
95% CI)
Cutoff Sensitivity Specificity PPVd NPVd Cutoff Sensitivity Specificity PPVd NPVd Cutoff Sensitivity Specificity PPVd NPVd
MoCA 
(85%, 
75%-92%)
<27 82 60 47 89 <23 41 96 81 79 <26 79 79 62 90
Total 
ADL-IS 
(68%, 
57%-78%)
>0.15 82 40 37 84 >1.21 18 96 65 73 >0.40 65 71 49 82
MoCA + 
Total 
ADL-IS 
(86%, 
76%-93%)f
>0.70 82 67 51 90 >0.42 65 94 82 86 >0.61 76 85 69 89
Abbreviations: ADL-IS = Activities of Daily Living-International Scale; AUC = area under the 2-D receiver operating characteristics curve; CI = confidence interval; MoCA = Montreal 
Cognitive Assessment (maximum score = 30); NPV = negative predictive value; PD-D = patients with Parkinson disease with dementia; PD-MCI = patients with Parkinson disease with 
mild cognitive impairment; PD-N = patients with Parkinson disease with normal cognition; PPV = positive predictive values.
a Lowest value with sensitivity and NPV at ~80% (base rate for PD-MCI vs PD-N = 30%; Dalrymple-Alford et al., 2011).
b Highest value with specificity and PPV at ~80% when available (base rate for PD-MCI vs PD-N = 30%; Dalrymple-Alford et al., 2011).
c Sensitivity+Specificity-100
d For PPV and NPV, estimated population base rate was 30% between PD-MCI vs PD-N.
e PD-MCI = 34 and PD-N = 48
fThe cut-off values obtained through logistic regression for optimal screening values, optimal diagnostic values and maximum accuracy are probability p values
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PD-D vs PD-MCI. When discriminating patients with PD-D from patients with PD-
MCI, excellent AUC were obtained for the MoCA, total ADL-IS, and the MoCA with 
total ADL-IS (Table 10). Importantly, the total ADL-IS (AUC difference of 10%, p = 
0.03), and the MoCA with total ADL-IS (AUC difference of 11%, p = 0.006) performed 
significantly better than the MoCA alone.  The total ADL-IS measure by itself performed 
almost maximally in terms of discriminating PD-D from PD-MCI (AUC = 98%), with 
improved sensitivity, specificity, PPV and NPV for optimal screening values and optimal 
diagnostic values compared to the MoCA by itself. When logistic regression was 
performed with the MoCA along with the total ADL-IS, a perfect discrimination was 
obtained between PD-D and PD-MCI (AUC = 100%). 
In any screening context, a full (total) ADL screen is unlikely. Thus further 
logistic regression analyses were performed to evaluate if the MoCA along with the final 
five ADL-IS items subset was good when discriminating patients suffering with PD-D 
from PD-MCI. The significant ADL items were Complex Medication (p < 0.01) and 
Muddled (p < 0.05) items out of the final five ADL-IS items. To derive a brief screening 
tool, the MoCA was first combined with Muddled and Complex Medication ADL-IS 
items. This analysis gave a high AUC (97%) that was significantly better than the MoCA 
by itself (AUC difference of 8%, p = 0.018). High sensitivity (88%) and good NPV 
(83%) at the optimal screening cut-off was obtained. Similarly good specificity (82%) 
and high PPV (89%) was obtained for optimal diagnostic value. This evidence suggests 
that the combination of the MoCA plus these two ADL items provides an excellent 
screen for cognitive status in PD.
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Table 10
Diagnostic performance of the MoCA, and ADL-IS between PD-D and PD-MCI for 1.5SD:2 one-domain MCI criterione
Optimal Screen Valuesa Optimal Diagnostic Valuesb Maximum Accuracy (Youden Index)c
Test (AUC,
95% CI)
Cut-off Sensitivity Specificity PPVd NPVd Cut-off Sensitivity Specificity PPVd NPVd Cut-off Sensitivity Specificity PPVd NPVd
MoCA (89%, 
77%-95%)
<23 92 59 77 83 <21 71 82 86 65 <22 83 71 81 74
Total ADL-IS 
(98%, 90%-
100%)
>1.62 83 100 100 80 >1.2 100 82 90 100 >1.32 96 88 92 93
MoCA + Total 
ADL-IS (100%, 
93%-100%) f
>0.01 83 100 100 80 >0.99 100 82 90 100 >0.90 100 97 98 100
MoCA + 
Muddled + 
Complex 
Medication 
(97%, 88%-
100%) f
>0.56 88 94 96 83 >0.73 92 82 89 87 >0.58 92 94 96 88
MoCA + 
Complex 
Medication 
(95%, 86%-
99%) f
>0.59 88 94 96 83 >0.79 92 82 89 87 >0.59 88 94 96 83
MoCA + 
Average of 4 
IADL items 
(93%, 83%-
98%) f
>0.78 92 76 85 86 >0.60 83 82 88 77 >0.79 96 74 84 92
Abbreviations: ADL-IS = Activities of Daily Living-International Scale; AUC = area under the 2-D receiver operating characteristics curve; CI = confidence interval; MoCA = Montreal Cognitive 
Assessment (maximum score = 30); NPV = negative predictive value; PD-D = patients with Parkinson disease with dementia; PD-MCI = patients with Parkinson disease with mild cognitive 
impairment; PD-N = patients with Parkinson disease with normal cognition; PPV = positive predictive values.
a Lowest value with sensitivity and NPV at ~80% (base rate for PD-D vs PD-MCI = 60%; Dalrymple-Alford et al., 2011).
b Highest value with specificity and PPV at ~80% when available (base rate for PD-D vs PD-MCI = 60%; Dalrymple-Alford et al., 2011).
c Sensitivity+Specificity-100
d For PPV and NPV, estimated population base rates was 60% between PD-D vs PD-MCI.
ePD-D = 24 and PD-MCI = 34
f The cut-off values obtained through logistic regression for optimal screening values, optimal diagnostic values and maximum accuracy are probability p values
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To examine the performance of the MoCA with either of the two ADL-IS items, 
MoCA with the Muddled ADL-IS item alone, and MoCA with the Complex Medication 
ADL-IS item by itself were analysed. However, the AUC obtained by the MoCA with 
only the Muddled ADL-IS (AUC = 90%) item was not better than the MoCA by itself 
(AUC difference of 2%, p = 0.467). Although, a high AUC was obtained when using the 
MoCA and the Complex Medication item (AUC = 95%), it was marginally non-
significant when compared to the MoCA questionnaire by itself (AUC difference of 6%, 
p = 0.066). For optimal screening values for MoCA with Complex Medication ADL-IS 
item, high sensitivity (88%) and good NPV (83%), and high specificity (94%) and PPV 
(96%) were obtained when compared to the MoCA by itself and the MoCA with 
Muddled ADL-IS item. Similarly, for optimal diagnostic values for the MoCA with
Complex Medication ADL-IS item, good specificity (82%) and high PPV (89%) and high 
sensitivity (92%) and NPV (87%) were obtained. Finally, the aim was to come up with a 
brief set of IADL items when the scores were not obtained for Complex Medication 
ADL-IS item. Therefore, a logistic regression was performed with the MoCA along with 
an average of four ADL-IS items (Muddled, Getting lost during travel, Multitasking, and 
Confusion) which resulted with a high AUC (93%) although again was not significantly 
greater than the MoCA by itself (AUC difference of 5%, p = 0.076). 
The conclusion from these analyses is that, for discriminating PD-MCI from PD-
N, the MoCA is a sufficiently suitable screening measure that is not improved by adding 
ADL measures. To distinguish PD-D from PD-MCI, a series of steps can be followed. 
MoCA and the full ADL-IS questionnaire can be administered to a patient suffering from 
PD, if enough time is available, which is not always the case. When time is limited and 
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depending on the possibility of answering the questions regarding the ADL-IS items, 
firstly, MoCA along with Muddled and Complex Medication ADL-IS items should be 
administered. Secondly, if no scores are obtained for Muddled, then MoCA along with 
Complex Medication ADL-IS item is sufficient to discriminate PD-D from PD-MCI. 
However, if no scores are obtained for Complex Medication item, then an average of four
ADL-IS items should be taken along with the MoCA. These steps will be equivalent to 
performing the MoCA with the 40 ADL-IS items and will give similar sensitivity and 
specificity that, even in the case of the MoCA plus four ADL items, are generally better 
than when the MoCA is conducted alone..
Clinicians and other health professionals would not refer to a logistic regression 
equation for clinical decision-making. Therefore, Tables 11-17 have been formed using 
the logistic regression equation to determine into which group a PD patient will fall 
taking into account the scores obtained for the MoCA along with the ADL-IS items. 
These tables can be simply looked up and are easy to use by any health professionals.
Tables 11-13 shows the grids (11.1 – 13.5) when MoCA, Muddled and Complex 
Medication ADL-IS item scores are obtained for optimal screening value, optimal 
diagnostic value and maximum accuracy values respectively for PD-N, PD-MCI and PD-
D. Table 14 shows the grids (14.1 – 14.3) when MoCA and only Complex Medication
ADL item scores are obtained for optimal screening values, optimal diagnostic value and 
maximum accuracy values for PD-N, PD-MCI and PD-D. Tables 15 – 17 shows the grids 
when MoCA and an average of four ADL-IS items scores for optimal screening values, 
optimal diagnostic values and maximum accuracy values for PD-N, PD-MCI and PD-D. 
For all the above grids, the dark grey areas represent the PD-N region, the light grey areas 
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are for PD-D, and the blue areas are PD-MCI. Note that the MoCA takes precedence to
distinguish PD-MCI from PD-N, and thus an upper barrier for any PD-D evaluation. 
Also, the MoCA cut-off varies across optimal screening values, optimal diagnostic values 
and maximum accuracy values.
For example, when a PD patient scores 26 on the MoCA along with scores of 3
and 0 on Muddled and Complex Medication ADL-IS items respectively, then that patient 
is more likely to be diagnosed as PD-MCI using the optimal screening values (see Table 
11 and grid 11.4). If only a score on Complex Medication ADL-IS item is obtained along 
with the MoCA, then a patient with a score of 20 on the MoCA and a score of 4 on 
Complex Medication ADL-IS item, then that patient is more likely to be diagnosed as 
PD-D using the optimal screening values (see Table 14 and grid 14.1). The tables reflect 
the fact that ADL items do not improve discrimination of PD-MCI from PD-N. These 
tables also show that discrimination between PD-D and PD-MCI are improved because of 
the greater overlap of the MoCA scores in these groups. The MoCA scores can be 
relatively low in some PD-MCI cases as long as the ADL scores remain relatively good. 
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Table 11
Optimal Screening Values: MoCA, Muddled and Complex Medication for PD-N, PD-MCI and 
PD-D for 1.5SD:2 one-domain MCI criterion*+#
11.1
MoCA; Muddled = 0
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
11.2
MoCA; Muddled = 1
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
11.3
MoCA; Muddled = 2
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
11.4
MoCA; Muddled = 3
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
11.5
MoCA; Muddled = 4
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
* Separation between PD-MCI and PD-N, see Table 9
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity is no 
longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
07/02/2011 Vineetha Uthamaputhiran
68266341
44
Table 12
Optimal Diagnostic Values: MoCA, Muddled and Complex Medication for PD-N, PD-MCI and 
PD-D for 1.5SD:2 one-domain MCI criterion*+ #
12.1
MoCA; Muddled = 0
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
12.2
MoCA; Muddled = 1
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
12.3
MoCA; Muddled = 2
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
12.4
MoCA; Muddled = 3
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
12.5
MoCA; Muddled = 4
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
* Separation between PD-MCI and PD-N, see Table 9
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity 
is no longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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Table 13
Maximum Accuracy (Youden Index) Values: MoCA, Muddled and Complex Medication for PD-
N, PD-MCI and PD-D for 1.5SD:2 one-domain MCI criterion*+#
13.1
MoCA; Muddled = 0
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
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pl
ex
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at
io
n 0
1
2
3
4
13.2
MoCA; Muddled = 1
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
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pl
ex
 
M
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io
n 0
1
2
3
4
13.3
MoCA; Muddled = 2
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
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ex
 
M
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n 0
1
2
3
4
13.4
MoCA; Muddled = 3
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
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io
n 0
1
2
3
4
13.5
MoCA; Muddled = 4
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
* Separation between PD-MCI and PD-N, see Table 9
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity is 
no longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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Table 14
Optimal Screen Values, Optimal Diagnostic Values and Maximum Accuracy (Younden Index): 
MoCA and Complex Medication for PD-N, PD-MCI and PD-D for 1.5SD:2 one-domain MCI 
criterion*+#
14.1
Optimal Screen Value
MoCA
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
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ex
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io
n 0
1
2
3
4
14.2
Optimal Diagnostic Value
MoCA
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
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n 0
1
2
3
4
14.3
Maximum Accuracy (Youden Index)
MoCA
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
* Separation between PD-MCI and PD-N, see Table 9
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity is no 
longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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Table 15
Optimal Screening Values: MoCA and Average of 4 ADL items for PD-N, PD-MCI and PD-D for 
1.5SD:2 one-domain MCI criterion*+#
MoCA
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
A
ve
ra
ge
 o
f 4
 A
D
L-
IS
 It
em
s
0.00
0.08
0.20
0.30
0.40
0.49
0.60
0.70
0.80
0.89
1.00
1.10
1.20
1.29
1.40
1.50
1.60
1.70
1.80
1.90
2.00
2.10
2.20
2.30
2.40
2.50
2.51
2.70
2.80
2.90
2.91
3.10
3.20
3.30
3.32
3.50
3.60
3.70
3.72
3.90
4.00
* Separation between PD-MCI and PD-N, see Table 9
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity is no 
longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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Table 16
Optimal Diagnostic Values: MoCA and Average of 4 ADL items for PD-N, PD-MCI and PD-
D for 1.5SD:2 one-domain MCI criterion*+#
MoCA
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
A
ve
ra
ge
 o
f 4
 A
D
L-
IS
 It
em
s
0.00
0.10
0.20
0.28
0.40
0.50
0.60
0.69
0.80
0.89
1.00
1.09
1.20
1.29
1.40
1.50
1.60
1.70
1.80
1.90
2.00
2.10
2.20
2.29
2.40
2.50
2.60
2.70
2.80
2.90
3.00
3.10
3.20
3.30
3.40
3.50
3.60
3.70
3.80
3.90
4.00
* Separation between PD-MCI and PD-N, see Table 9
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity is no 
longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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Table 17
Maximum Accuracy (Younden Index): MoCA and Average of 4 ADL items for PD-N, PD-
MCI and PD-D for 1.5SD 2 one-domain MCI criterion*+#
MoCA
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
A
ve
ra
ge
 o
f 4
 A
D
L-
IS
 It
em
s
0.00
0.10
0.13
0.30
0.40
0.50
0.53
0.70
0.80
0.90
0.94
1.10
1.20
1.30
1.34
1.50
1.60
1.70
1.74
1.90
2.00
2.10
2.15
2.30
2.40
2.50
2.55
2.70
2.80
2.90
2.96
3.10
3.20
3.30
3.36
3.50
3.60
3.70
3.77
3.90
4.00
* Separation between PD-MCI and PD-N, see Table 9
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity is no 
longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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1.5SD:1 two-domain MCI criterion
This MCI criterion is an alternative criterion and is defined as 1.5 SD below normative 
data in at least one measure but in two domains. The main results are presented below.
Most of the tables are included in the Appendix.
Demographics
In comparison with the standard VDV criterion, all the demographic variables were 
similar apart from the mean scores on age and Geriatric Depression Scale (Table 4). The 
mean age for all the three PD groups and the controls were similar. For the Geriatric 
Depression Scale, the mean score of the two cognitively normal groups were lower than 
the PD-MCI and PD-D.
Cognitive Assessments
All the measures for mental status tests, functional status, dementia assessment and 
neuropsychological domains for 1.5SD:1 criterion were similar to 1.5SD:2 criterion
(Appendix 4). The only difference that was found between these two criteria was on the 
ADL-IS measure between PD-N and healthy controls where the means for PD-N was 
similar to healthy controls.
Activities of Daily Living
Appendix 5 shows the means for 13 categories and 40 individual items of the ADL-IS
measure. The means on the total ADL-IS scores for this criteria were similar to the 
standard VDV criterion. Firstly, analysing the means in all 13 categories, the scores were 
similar to the previous criterion apart from three categories. For the household activities 
and organisation categories, the PD-MCI group had similar means to PD-N. For the 
reading category, the PD-MCI group had significantly higher scores than the PD-N 
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patients. Secondly, analysing the 40 individual items on the ADL-IS among the 13 
categories, again similar performances were observed by using both the criteria apart 
from five individual items. On all of these five individual ADL-IS items, PD-MCI and 
the PD-N group had similar scores.
Similar steps to the standard VDV criterion were followed to exclude variables in 
order to obtain the five ADL items that were combined with the MoCA for the analysis 
between PD-D vs PD-MCI, and PD-MCI vs PD-N. Appendix 6 shows the number of 
patients who scored from 0 to 4 on the 40 ADL-IS items and their reasons for exclusion.
Firstly, seven items and a basic ADL item were excluded because motor symptoms of PD 
were thought to influence these activities of daily living items. These items were same as 
the previous criterion. Secondly, 21 items were excluded because these items had 5% of 
missing data in any group except for Multitasking ADL-IS item. Even though 
Multitasking item had 5% of missing data in the PD-MCI group, this item was retained to 
keep the analysis similar to the 1.5SD:2 criterion. Finally, if one category had more than 
two items, then two items that were closer on the basis of relevance to dementia were 
kept. After all the exclusions, a total of eight IADL items (Confusion, Complex Items, 
Muddled, Preserve, Complex Medication, Get Lost, Multitasking and Forms) were 
remaining.
To keep the analysis consistent with the standard VDV criterion the same final 
five ADL-IS items were kept. These were Complex medication, Muddled, Getting Lost, 
Multitasking, and Confusion. The tolerance values for these five IADL items are shown 
in Appendix 7. Again, for all the five IADL items, the tolerance values were above 0.20
(http://faculty.chass.ncsu.edu/garson/PA765/regress.htm). The tolerance of PD-D vs PD-
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MCI for the five IADLs ranged from a minimum of 0.58 to a maximum of 0.90, whereas 
the tolerance of PD-MCI vs PD-N ranged from a minimum of 0.50 to a maximum of 
0.80.
Analysis of MoCA with Activities of Daily Living
PD-MCI vs PD-N. Table 18 indicates the diagnostic performances of the MoCA, total 
ADL-IS, and the MoCA when combined with total ADL-IS score between PD-MCI and 
PD-N for this alternative MCI criteria. In comparison with the standard VDV criterion, 
lower AUC were obtained for the MoCA (78%), total ADL-IS score (66%) and when the 
MoCA was combined with total ADL-IS score (78%). The main differences were evident 
in the percentages for sensitivity, specificity, PPV and NPV for the MoCA and the 
MoCA with total ADL-IS. For the MoCA, high sensitivity (87%) and NPV (88%) but 
poor specificity (40%) and PPV (38%) at the optimal screening cut-off were obtained. 
Low sensitivity (56%) and moderate PPV (68%) with high specificity (88%) and good 
NPV (83%) were obtained for the MoCA at the maximum accuracy values. For the 
MoCA with total ADL-IS, good sensitivity (82%) and high NPV (86%) but poor
specificity (49%) and PPV (41%) at the optimal screening cut-off were obtained. For the 
optimal diagnostic values, poor sensitivity (44%) with high specificity (95%), good PPV 
(80%) and good NPV (80%) were evident. For comparisons with the standard VDV 
criterion refer to Table 9.
Further analysis was done using logistic regression similar to the previous 
criterion. When logistic regression was performed with the MoCA and the final five 
ADL-IS items, none of the ADL-IS items significantly contributed to the MoCA score.
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Table 18
Diagnostic performance of the MoCA, total ADL-IS and the MoCA along with the total ADL-IS between PD-MCI and PD-N for 1.5SD:1 two-domain MCI 
criterione
Optimal Screen Valuesa Optimal Diagnostic Valuesb Maximum Accuracy (Youden Index) c
Test 
(AUC, 
95% CI)
Cut-
off
Sensitivity Specificity PPVd NPVd Cut-off Sensitivity Specificity PPVd NPVd Cut-off Sensitivity Specificity PPVd NPVd
MoCA 
(78%, 
67%-
86%)
<28 87 40 38 88 <24 46 95 81 81 <25 56 88 68 83
Total 
ADL-IS 
(66%, 
55%-
76%)
>0.1 82 37 36 83 >1.21 15 95 59 72 >0.4 62 72 49 81
MoCA + 
Total 
ADL-IS 
(78%, 
68%-
87%)f
>0.70 82 49 41 86 >0.27 44 95 80 80 >0.44 62 88 69 84
Abbreviations: ADL-IS = Activities of Daily Living-International Scale; AUC = area under the 2-D receiver operating characteristics curve; CI = confidence interval; MoCA = Montreal 
Cognitive Assessment (maximum score = 30); NPV = negative predictive value; PD-D = patients with Parkinson disease with dementia; PD-MCI = patients with Parkinson disease with 
mild cognitive impairment; PD-N = patients with Parkinson disease with normal cognition; PPV = positive predictive values.
a Lowest value with sensitivity and NPV at ~80% (base rate for PD-MCI vs PD-N = 30%, Dalrymple-Alford et al., 2011).
b Highest value with specificity and PPV at ~80% when available (base rate for PD-MCI vs PD-N = 30%, Dalrymple-Alford et al., 2011).
c Sensitivity+Specificity-100
d For PPV and NPV, estimated population base rates was 30% for PD-MCI vs PD-N.
e PD-MCI = 39 and PD-N = 43
f The cut-off values obtained through logistic regression for optimal screening values, optimal diagnostic values and maximum accuracy are probability p values
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Therefore, same conclusions as suggested with the standard VDV criterion are evident by 
using this 1.5SD:1 criterion which is the MoCA is a sufficiently suitable screening 
measure to discriminate PD-MCI from PD-N and is not improved by adding ADL items. 
PD-D vs PD-MCI. In comparison to the standard VDV criteria, similar results were 
obtained by this criterion for the MoCA, the total ADL-IS and the MoCA with total 
ADL-IS (Table 19). Again, similar results were obtained in terms of the sensitivity, 
specificity, PPV and NPV for optimal screening values and optimal diagnostic values for 
the MoCA, total ADL-IS and the MoCA with total ADL-IS. 
Similar to the standard VDV criterion, further logistic regression analyses were 
performed by using the current criterion. The results obtained by using 1.5SD:1 criterion
were similar to the previous criterion. The main results were 1) the MoCA with Muddled 
and Complex Medication ADL-IS items gave a high AUC (98%) and was significantly 
better than the MoCA by itself (AUC difference of 7%, p = 0.020), 2) the AUC obtained 
by the MoCA with only the Muddled ADL-IS (AUC = 92%) item was however not 
significantly better than the MoCA by itself (AUC difference of 2%, p = 0.522), 3) the 
MoCA along with only Complex Medication ADL-IS item gave a high AUC (96%), but 
it was not significantly better than the MoCA instrument by itself (AUC difference of 
5%, p = 0.091) and 4) the MoCA along with an average of four ADL-IS items (Muddled, 
Getting lost during travel, Multitasking, and Confusion) resulted with a high AUC (94%) 
but was not significantly greater than the MoCA by itself (AUC difference of 4%, p = 
0.082). The percentages obtained for sensitivity, specificity, PPV and NPV for optimal 
screening values and optimal diagnostic values were mostly similar to the standard VDV 
criterion.
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Table 19
Diagnostic performance of the MoCA, and ADL-IS between PD-D and PD-MCI for 1.5 SD 1 two-domain MCI criterion e
Optimal Screen Valuesa Optimal Diagnostic Valuesb Maximum Accuracy (Youden Index) c
Test (AUC, 
95% CI)
Cut-off Sensitivity Specificity PPVd NPVd Cut-off Sensitivity Specificity PPVd NPVd Cut-off Sensitivity Specificity PPVd NPVd
MoCA (91%, 
81%-97%)
<23 92 64 79 84 <21 75 85 88 69 <22 88 74 84 80
Total ADL-IS 
(98%, 91%-
100%)
>1.62 83 100 100 80 >1.2 100 85 91 100 >1.32 96 90 93 94
MoCA + Total 
ADL-IS (100%, 
94%-100%)f
>0.01 83 100 100 80 >0.99 100 82 89 100 >0.90 100 97 98 100
MoCA + 
Muddled + 
Complex 
Medication 
(98%, 91%-
100%)f
>0.64 88 95 96 84 >0.79 96 82 89 93 >0.71 96 90 93 94
MoCA + 
Complex 
Medication 
(96%, 87%-
99%)f
>0.56 88 95 96 84 >0.81 96 85 90 93 >0.70 92 92 95 88
MoCA + 
Average of 4 
IADL items 
(94%, 86%-
99%)f
>0.61 88 85 90 82 >0.62 88 82 88 81 >0.82 96 77 86 93
Abbreviations: ADL-IS = Activities of Daily Living-International Scale; AUC = area under the 2-D receiver operating characteristics curve; CI = confidence interval; MoCA = Montreal Cognitive 
Assessment (maximum score = 30); NPV = negative predictive value; PD-D = patients with Parkinson disease with dementia; PD-MCI = patients with Parkinson disease with mild cognitive 
impairment; PD-N = patients with Parkinson disease with normal cognition; PPV = positive predictive values.
a Lowest value with sensitivity and NPV at ~80% (base rate for PD-D vs PD-MCI = 60%, Dalrymple-Alford et al., 2011).
b Highest value with specificity and PPV at ~80% when available (base rate for PD-D vs PD-MCI = 60%, Dalrymple-Alford et al., 2011).
c Sensitivity+Specificity-100
d For PPV and NPV, estimated population base rates was 60% between PD-D vs PD-MCI.
e PD-D = 21 and PD-MCI = 39 
f The cut-off values obtained through logistic regression for optimal screening values, optimal diagnostic values and maximum accuracy are probability p values
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The same conclusions obtained with the 1.5SD:2 criterion were evident by using 
the 1.5SD:1 two-domain criterion.  Again these were 1) the MoCA is a sufficiently
suitable screening measure that is not improved by adding ADL measures for 
discriminating PD-MCI from PD-N, 2) For distinguishing PD-D from PD-MCI, MoCA 
and the full ADL-IS questionnaire can be administered to a patient suffering from PD.
When time is limited and depending on the possibility of answering the questions 
regarding the ADL-IS items, MoCA along with Muddled and Complex Medication ADL-
IS items should be administered. If no scores are obtained for Muddled, then MoCA 
along with Complex Medication ADL-IS item is sufficient to discriminate PD-D from 
PD-MCI. However, if no scores are obtained for Complex Medication item, then an 
average of four ADL-IS items should be taken along with the MoCA. 
Similar to the standard VDV criterion, Tables 20 and 21, and tables in Appendix 8
and 9 has been formed using the logistic regression equation to determine which group a 
PD patient will fall taking into account the scores obtained for the MoCA along with the 
ADL-IS items. Table 20 and tables in Appendix 8 shows the grids when the MoCA, 
Muddled and Complex Medication ADL-IS item are obtained for optimal screening 
values, optimal diagnostic values and maximum accuracy values respectively for PD-N, 
PD-MCI and PD-D. Table 21 shows the grids (21.1 – 21.3) when the MoCA and only 
Complex Medication scores are obtained for optimal screening values, optimal diagnostic 
values and maximum accuracy values for PD-N, PD-MCI and PD-D. Appendix 9 shows 
the grids when the MoCA and an average of four ADL-IS items scores for optimal 
screening values, optimal diagnostic values and maximum accuracy values for PD-N, 
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PD-MCI and PD-D. For all the above grids, the dark grey areas represent the PD-N
region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
When comparing both the grids formed for the two MCI criteria, the main 
difference was that for the alternative criterion there are slightly more boxes in a grid that 
are classified as PD-MCI. This is because of small differences in the cut-off values 
obtained between PD-MCI vs PD-N and PD-D vs PD-MCI. For example, usinf the 
alternative criterion for the screening cut-off a PD patient who scores 27 on the MoCA 
along with scores of 3 and 0 on Muddled and Complex Medication ADL-IS items 
respectively is classified as PD-MCI (see Table 20 and grid 20.4) whereas on the 
standard VDV criterion, the same patient would be diagnosed as PD-N (Table 9 and 11).
Note, however that this alternative criterion (1.5SD:1 in two domains) has poor 
specificity (40%) compared to 60% for the current VDV criterion (1.5SD:2 in one 
domain) with respect to the screening cut-off (Tables 9 and 18). If only a score on 
Complex Medication ADL-IS item is obtained along with the MoCA, then a patient with 
a score of 25 on the MoCA and a score of 4 on Complex Medication ADL-IS item is 
more likely to be diagnosed as PD-MCI using the alternative criterion (see Table 21 and 
grid 21.1) whereas the same patient would be diagnosed as PD-D by using the 1.5SD:2 
criterion (Table 9 &14).
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Table 20
Optimal Screening Values: MoCA, Muddled and Complex Medication for PD-N, PD-MCI and 
PD-D for 1.5SD:1 two-domain MCI criterion*+#
20.1
MoCA; Muddled = 0
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
ic
at
io
n 0
1
2
3
4
20.2
MoCA; Muddled = 1
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
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4
20.3
MoCA; Muddled = 2
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
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3
4
20.4
MoCA; Muddled = 3
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
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20.5
MoCA; Muddled = 4
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
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ex
 
M
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io
n 0
1
2
3
4
* Separation between PD-MCI and PD-N, see Table 18
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity 
is no longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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Table 21
Optimal Screen Values, Optimal Diagnostic Values and Maximum Accuracy (Younden Index): 
MoCA and Complex Medication for PD-N, PD-MCI and PD-D for 1.5SD:1 two-domain MCI 
criterion*+#
21.1
Optimal Screen Value
MoCA
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
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ex
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3
4
21.2
Optimal Diagnostic Value
MoCA
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
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3
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21.3
Maximum Accuracy (Youden Index)
MoCA
< 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
C
om
pl
ex
 
M
ed
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at
io
n 0
1
2
3
4
* Separation between PD-MCI and PD-N, see Table 18
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity 
is no longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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Discussion
The current study is one of the first attempts to create a short assessment procedure for 
the diagnosis of PD-D validated by a large independent battery of neuropsychological 
tests and measures of everyday functional status. The present study provides strong 
evidence that the MoCA produces a good discrimination especially for discriminating 
PD-D from PD-MCI. Moreover, MoCA along with the 40 ADL-IS items shows perfect 
discrimination between PD-D and PD-MCI, followed in terms of overall accuracy by 
MoCA with Muddled and Complex Medication ADL-IS items, MoCA and Complex 
Medication ADL-IS item, and MoCA with an average of 4 ADL-IS items. These results 
suggest that brief measures of everyday functional status along with MoCA are effective 
screens when discriminating patients with different cognitive status, especially PD-D 
from PD-MCI. To discriminate PD-MCI from PD-N, the current study has shown that the 
MoCA is a sufficiently suitable screening measure that is not improved by adding ADL 
items. 
There has been growing evidence that MoCA is a good discriminator for 
cognitive impairment in PD. A recent study by Dalrymple-Alford et al. (2010), who used 
the standard VDV criterion, reported that the MoCA performed generally better than the 
MMSE and the PD-focussed SCOPA-COG, especially when discriminating PD-MCI 
from the patients with little or minimal cognitive impairment (PD-N). Dalrymple-Alford 
and colleagues (2011) suggested that for screening cognition in PD, the cut-off for MoCA 
between the PD-MCI and PD-N was <26 with high sensitivity (90%) and good specificity 
(75%) although with moderate PPV (61%) but high NPV (95%). In the current study, the 
screening cut-off for MoCA between PD-MCI and PD-N was <27 with good sensitivity 
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(82%) but moderate specificity (60%), again with poor PPV (47%) but high NPV (89%). 
One reason for small difference in the cut-off values for the MoCA and the low 
diagnostic performances in the current study may be sample size although both analyses 
gave <26 for the Youden Index. In the Dalrymple-Alford et al (2011) study, there were 
72 patients with PD-N whereas in the current study there were only 48 PD-N patients
because many were excluded due to not having been assessed on everyday functional 
measures. The PD-D screening cut-off proposed by Dalrymple-Alford et al. (2010) was 
<21 with good sensitivity (81%) and high specificity (95%) along with high PPV (87%)
and NPV (92%). However, in the current study the cut-off was <23 for the MoCA with 
high sensitivity (92%) but poor specificity (59%) although good PPV (77%) and good 
NPV (83%). Again this increase in the cut-off can be explained due to the difference in 
the sample size used for the comparison. In Dalrymple-Alford et al. (2010) study, the 
non-dementia group (PD-N and PD-MCI combined) was analysed against the PD-D 
patients, which meant that they had 93 patients without dementia and 21 PD-D patients. 
In this study the PD-D was analysed against the PD-MCI and there were 21 PD-D 
patients and 34 PD-MCI patients. 
The validity of the MoCA and MMSE in PD was also tested by Hoops et al.
(2009) but they distinguished PD-N from cognitively impaired patients (PD-MCI and
PD-D).  Their proposed optimal screening cut-off for the MoCA was 26/27 (sensitivity = 
90% and specificity = 53%) and optimal diagnostic cut-off was 17/18 (sensitivity = 18% 
and specificity = 99%).  This poor specificity for the optimal screening cut-off and low 
sensitivity for the diagnostic cut-off might be because the reliability of their assignment 
to cognitive status groups was poor due to the use of few neuropsychological tests and 
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poor evaluation of functional status (no data collected from a significant other), which is 
an important component to make a diagnosis of PD-D according to the MDS criteria 
(Dubois et al., 2007). Another, smaller study showed that the MoCA and MMSE 
performed equally when identifying impairments but this might be due to inclusion of 
patients with dementia, as several low scores were identified (Gill et al., 2008). Other 
studies that have analysed MoCA in PD have resulted in uncertain validation of cognitive 
status (Nazem et al., 2009; Zadikoff et al., 2008).
A recent study examined the value of everyday functioning using the Reisberg’s 
ADL-IS measure in amnestic and non-amnestic MCI patients along with other memory 
deficits in AD (Schmitter-Edgecomber et al., 2009). The study examined the 13 
categories of the ADL-IS instrument among 27 amnestic MCI patients, 15 non-amnestic 
MCI patients and 42 healthy controls. The results indicated that greater difficulties with 
complex IADLs were reported by significant others for the amnestic and non-amnestic 
MCI groups in comparison to the control group. Further analysis revealed that amnestic 
and non-amnestic MCI patients had significantly poor performance than the control 
group in the domains of conversation, household activities, medication, social 
functioning, telephone, and organisation. In conclusion, the study indicated that the ADL-
IS instrument was sensitive to assessment of IADL difficulties in discriminating both the 
amnestic and non-amnestic MCI individuals from the control group. Similarly, the 
present study suggests that there are some differences between PD-MCI vs PD-N in the 
ADL item (Tables 5 & 6) but the ADL-IS items does not add to value of the MoCA. 
Moreover, the ADL-IS measure by itself performed beteer in erms of discriminating PD-
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D from PD-MCI (AUC = 98%). Additionally, an excellent discrimination was obtained 
when the MoCA was combined with the ADL-IS measure (AUC = 100%).
Studies have used different questionnaires to measure the functional status of 
activities of daily living for MCI, especially in the context of AD. These studies have, for 
example, used two 4 IADL instruments (Li et al., 2006; Peres et al., 2008) and the FAQ 
(Steenland et al., 2008). In the study by Li et al. (2006), high sensitivity (86%) and 
specificity (85%) was obtained for detecting combined AD-MCI for their brief 
instrument when they included a question concerning memory impairment. The second 
study proved that four IADLs such as telephone, transportation, medication and finances
– could constitute an early marker of developing dementia (Peres et al., 2008). Steenland 
et al. (2008) developed a rapid screening instrument for MCI and dementia in AD. The 
study used the Mini-Cog and FAQ instruments to generate grids that discriminated 
among unimpaired, MCI and dementia patients. The demented group cut-offs have high
sensitivity (89%) and specificity (90%) when compared against the unimpaired group. In 
conclusion, these studies suggest that having a restricted number of IADLs may be an 
easy and useful tool for screening patients who are progressing to dementia, similar to the 
current study. The scores on 4 IADL and the FAQ questionnaire developed by Li et al. 
(2006) and Pfeffer et al. (1982) respectively, were also obtained for some patients in this 
study. As, stated, however, due to the lack of time and the restricted number of patients 
with scores on these measures, they were not compared with the MoCA. 
A similar attempt to validate a short procedure for screening for PD-D in routine 
clinical practice was recently reported by Dujardin and colleagues (2010). In that study,
188 patients suffering from PD underwent a standard clinical examination, a short 
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cognitive functional assessment and an abbreviated evaluation of cognitive functions and 
behaviour, unlike the detailed evaluations used in the current study. The suspected 
presence or absence of dementia was recorded after each step. Their results suggested 
that, by using a short battery of tests in routine clinical practice, it is possible to diagnose 
PD-D, with similar sensitivity and specificity as in their slightly more extensive 
evaluation. This suggestion is similar to the results of this study where the data indicates 
that by administering the easy-to use MoCA instrument along with a few activities of 
daily living items, it is possible to discriminate especially PD-D from the PD-MCI 
patients. 
The criterion used to diagnosis PD-D in the current study is well established and
is based on the MDS guidelines (Dubios et al., 2007). The diagnosis of PD-D was based 
on significant impairment (operationally, -2.0 SD below normative data) in at least two 
cognitive domains, supporting evidence from two dementia assessment tests (DRS-2 and 
ADAS-Cog) together with information relevant to everyday function from a significant 
other (ADL-IS; Reisberg et al., 2001), Clinical Dementia Rating (CDR), and Global 
Deterioration Scale; Morris, 1993).
Controversies exist as to the criteria for the diagnosis of PD-MCI. An array of 
different MCI criteria are used across different PD studies (compared in Dalrymple-
Alford et al., 2011; Figure 2). The number of PD patients that are diagnosed as PD-MCI 
will vary with the different number of MCI criteria used. One commonly used criterion to 
diagnose PD-MCI is when a patient scores at 1.5 SD or more below normative data in a 
single measure in any domain (1.5SD:1; Aarsland, Bronnick, Williams-Gray, Weintraub, 
Marder, Kulisevsky, Burn, Barone, Pagonabarrage, Allcock, Santangelo, Foltynie, 
Vineetha Uthamaputhiran
68266341
65
Janvin, Larsen, Barker, & Emre, 2010). If this criterion was used in this study, then 48% 
of the patients in our PD-N group would have been diagnosed as PD-MCI, and 32% of 
healthy controls would also have been diagnosed as MCI. That is, this Aarsland et al. 
(2010) criterion may be inappropriate because 32% of our healthy controls who have 
intact cognition will be labelled MCI, which suggests that it is important to have a 
healthy control group when evaluating MCI criteria. 
Figure 2: This figure is reproduced from Dalrymple-Alford et al., 2011 which shows the global Z scores 
across four cognitive domains for all their participants. On the far left the individual scores for all the 
controls and non-dementia PD patients are shown whereas on the far right the PD-D patients are shown. 
Controls and non-dementia patients classified as MCI using 12 neuropsychological criteria are shown in 
the main body of the figure. For example in the above figure, 1SD:1 criterion is very liberal, as most PD 
and many controls are captured. Meanwhile, 2SD:2 is very conservative.
A similar criterion that has also been used in various studies is when an average 
score that fell 1.5 SD below was obtained by controls in 1 domain (1.5SD:Ave; Aarsland
et al., 2010). Aarsland et al. (2010) study suggested that 26% of PD-MCI were identified 
by using the 1.5SD:Ave criteria, even though variable range of percentages were seen at 
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different centres (20%-39%). However, this criterion identified 72% of PD-MCI among 
the nondemented group in the current study. By constrast, the standard VDV criterion
produced a 41% proportion of PD-MCI among the nondemented group in the current 
study (this value is higher than Figure 2 because that study included many early PD 
cases). Compared to the Aarsland et al. (2010) summary of other research centres, the 
current study used more domains and a more extensive battery of neuropsychological 
tests.  The VDV research group are not able to pin-point any particular measure that 
would show more deficits in the PD-MCI population. But all measures appeared sensitive 
to impairment, especially attention and memory deficits that became more discriminating 
with our more strict criterion (Dalrymple-Alford et al., 2011). When using either 1.5SD:1 
or 1.5SD:Ave single domain MCI criteria, it is clear that many of our patients with intact 
cognition judging by their overall cognitive (z) scores would be classified as MCI 
criteria.
Two more strict criteria were used in this study to analyse the data: 1) 1.5SD:2 
one-domain (1.5 SD below normative data on two measures within at least one of four 
cognitive domains – the standard VDV criterion) and 2) 1.5SD:1 two-domain (1.5 SD 
below normative data in at least one measure but in two domains – our alternative VDV 
criterion). Although the unber of “uncertain” cases is low for discriminating PD-MCI 
from PD-N, the standard VDV criterion was better overall than the alternative criterion
especially for the MoCA, as well as the MoCA with total ADL-IS items (Tables 9 and 
18). Both the criteria excellently discriminated PD-D from the PD-MCI patients for the 
MoCA, total ADL-IS, and MoCA with the other ADL-IS items. For optimal screening 
values and the optimal diagnostic values, MoCA had similar cut-off values (<23/30 and 
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<21/30 respectively) for both MCI criteria between PD-D vs PD-MCI. The sensitivity,
specificity, PPV and NPV were all similar when using both the criteria, for the MoCA, 
and the MoCA with the ADL-IS items.  The data suggest that these two criteria (1.5SD:2 
or 1.5SD:1) provide better balanced criteria to diagnose MCI than some of the other 
commonly used criteria.
There are a number of limitations in the current study. Firstly, one of the main 
limitations is the sample size. In order to replicate the results obtained in the current 
study, larger sample sizes are necessary especially for PD-MCI and PD-D. Secondly,
when calculating the positive and the negative predictive value, the base rate used for 
PD-MCI and PD-D were uncertain and depend on the specific criteria used. Thirdly, it is 
unsure how PD medications influence the MoCA and should be addressed when using 
the cut-off values proposed by the current study. Lastly, it is not known whether the 
patients diagnosed as PD-MCI will progress to PD-D. Hence, longitudinal studies need to 
be conducted to address these issues. 
One of the future recommendations would be to analyze the MoCA along with 
other activities of daily living questionnaires, such as the FAQ, and to examine if the 
measure along with the MoCA will produce the same results as in the current study or 
even further improve the discrimination between PD-MCI and PD-N.  Another important 
suggestion would be to look at some of the neuropsychological measures, especially tests 
that measure executive functions and visuospatial function, and to evaluate if these 
measures predict the decline of activities of daily living in PD-MCI and PD-D.
In conclusion, the current study indicates that MoCA along with a restricted 
number of IADLs from the Reisberg instrument may be useful to improve the 
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discrimination between PD-D from PD-MCI. The MoCA is a sufficiently suitable 
screening measure for discriminating PD-MCI from PD-N and is not improved by adding 
ADL measures. For distinguishing PD-D from PD-MCI, the MoCA and the full ADL-IS 
questionnaire can be administered to a patient suffering from PD. When time is limited 
and depending on the possibility of answering the questions regarding the ADL-IS items, 
the MoCA along with the Muddled and Complex Medication ADL-IS items should be 
administered. When no scores are obtained for Muddled, then MoCA along with 
Complex Medication ADL-IS item is sufficient to discriminate PD-D from PD-MCI. 
However, if no scores are obtained for Complex Medication item, then an average of four 
ADL-IS items should be taken along with the MoCA.
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Activities of Daily Living International Scale (ADL-IS)
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Appendix 3
Logit Transformation Table
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Appendix 4
Mental status tests, functional status, dementia assessment and neuropsychological domains for the three PD groups and Controls for 
1.5SD:1 two-domain MCI criterion+
HC
(n = 45)
PD-N 
(n = 43)
PD-MCI (2)
(n = 39)
PD-D 
(n = 24)
ANOVA/Kruskal-
Wallis
Adjacent pairwise 
comparisons *
Mental status tests
MoCA 27.29
(1.93)
26.88
(2.04)
23.90
(3.06)
17.29
(4.05)
F3,147 = 84.66, p < 0.001 HC = PD-N > PD-MCI > PD-D
MMSE-Sevens 28.60
(1.59)
28.09
(1.72)
26.28
(2.45)
22.91
(2.84)
F3,147 = 44.34, p < 0.001 HC = PD-N > PD-MCI > PD-D
MMSE-World 29.13
(1.01)
28.74
(1.33)
27.49
(1.76)
24.13
(3.07)
F3,147 = 48.19, p < 0.001 HC = PD-N > PD-MCI > PD-D
SCOPA-COG 34.15
(4.07)
31.95
(4.12)
26.28
(4.23)
15.35
(4.98)
F3,135 = 104.38, p < 0.001 HC > PD-N > PD-MCI > PD-D
Functional status
ADL-IS 0.21
(0.21)
0.42
(0.54)
0.66
(0.50)
1.99
(0.45)
F3,131 = 80.04, p < 0.001 HC = PD-N < PD-MCI < PD-D
CDR-Box 0.02
(0.09)
0.48
(1.12)
1.32
(1.09)
7.27
(2.54)
F3,131 = 158.51, p < 0.001 HC = PD-N < PD-MCI < PD-D
GDS 1.00
(0.00)
1.18
(0.38)
2.05
(0.90)
4.21
(0.83)
F3,129 = 145.34, p < 0.001 HC = PD-N < PD-MCI < PD-D
Dementia assessment
ADAS-COG 4.73
(1.80)
6.19
(2.50)
9.20
(3.79)
21.45
(8.09)
F3,135 = 86.40, p < 0.001 HC = PD-N < PD-MCI < PD-D
DRS–2 (AEMSS) 13.06
(2.16)
12.37
(1.86)
10.33
(2.06)
4.96
(2.68)
F3,135 = 79.68, p < 0.001 HC = PD-N > PD-MCI > PD-D
Neuropsychological domains
Executive Function 0.87 0.43 -0.36 -1.98 F3,147 = 145.12, p < 0.001 HC > PD-N > PD-MCI > PD-D
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(0.47) (0.65) (0.65) (0.54)
Attention, working memory, and 
processing speed
0.36
(0.46)
-0.03
(0.43)
-0.82
(0.47)
-1.89
(0.55)
F3,147 = 139.82, p < 0.001 HC > PD-N > PD-MCI > PD-D
Learning and Memory 0.93
(0.76)
0.20
(0.73)
-0.68
(0.76)
-1.77
(0.65)
F3,147 = 81.60, p < 0.001 HC > PD-N > PD-MCI > PD-D
Visuospatial/visuoperceptual 0.57
(0.40)
0.49
(0.37)
-0.32
(0.59)
-1.23
(0.80)
F3,147 = 78.37, p < 0.001 HC = PD-N > PD-MCI > PD-D
Aggregate mean score across the 
4 domains
0.68
(0.36)
0.27
(0.38)
-0.61
(0.39)
-1.72
(0.51)
F3,147 = 222.82, p < 0.001 HC > PD-N > PD-MCI > PD-D
Abbreviations: ADAS-COG = Alzheimer’s Disease Assessment Scale-Cognition; ADL-IS = Activities of Daily Living-International Scale; ANOVA = 
analysis of variance; CDR = Clinical Dementia Rating; DRS-2 = Dementia Rating Scale-2, using age-and education-adjusted standard scores; GDS = 
Global Deterioration Scale; HC = healthy age- and education-matched controls; MMSE = Mini-Mental State Examination; MoCA = Montreal 
Cognitive Assessment; PD-D = patients with Parkinson disease with dementia; PD-MCI = patients with Parkinson disease with mild cognitive 
impairment; PD-N = patients with Parkinson disease with normal cognition; SCOPA-COG = Scales for Outcomes in Parkinson disease-Cognition.
+ Values are mean (SD)
* p < 0.05 for post hoc test
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Appendix 5
Means and Standard Deviations for the 40 ADL-IS Individual Items for the three PD groups for 1.5SD:1 two-domain 
MCI criterion +
PD-N 
(n = 43)
PD-MCI (2)
(n = 39)
PD-D 
(n = 24)
ANOVA/Kruskal-
Wallis
Adjacent pairwise 
comparisons *
Total ADL-IS 0.42
(0.54)
0.66
(0.50)
1.99
(0.45)
F2,103 = 80.06, p < 0.001 PD-N < PD-MCI < PD-D
Conversation
Converse 0.37
(0.66)
0.54
(0.68)
1.33
(0.82)
F2,103 = 15.14, p < 0.001 PD-N = PD-MCI < PD-D
Wordfinding 0.33
(0.64)
0.41
(0.68)
1.17
(0.98)
F2,102 = 10.78, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.35
(0.59)
0.47
(0.56)
1.25
(0.81)
F2,103 = 16.62, p < 0.001 PD-N = PD-MCI < PD-D
Recreation
Operating TV 0.14
(0.52)
0.37
(0.67)
1.46
(1.14)
F2,100 = 23.70, p < 0.001 PD-N = PD-MCI < PD-D
Recalling TV 0.23
(0.65)
0.49
(0.64)
1.18
(0.85)
F2,101 = 13.71, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.19
(0..51)
0.44
(0.52)
1.33
(0.83)
F2,102 = 28.03, p < 0.001 PD-N = PD-MCI < PD-D
Self-Care
Cleaning clothes 0.26
(0.63)
0.40
(0.79)
1.33
(1.49)
F2,101 = 10.67, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.26
(0.63)
0.40
(0.79)
1.33
(1.49)
F2,101 = 10.67, p < 0.001 PD-N = PD-MCI < PD-D
Household Activities
Placing Items 0.26
(0.62)
0.41
(0.64)
1.25
(1.26)
F2,101 = 12.13, p < 0.001 PD-N = PD-MCI < PD-D
Household Tasks 0.21
(0.51)
0.41
(0.82)
1.78
(1.24)
F2,102 = 28.99, p < 0.001 PD-N = PD-MCI < PD-D
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Confusion 0.47
(1.01)
0.87
(0.78)
1.83
(1.05)
F2,102 = 16.38, p < 0.001 PD-N = PD-MCI < PD-D
Complex Items 0.56
(0.96)
0.79
(1.07)
2.38
(0.97)
F2,102 = 27.41, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.37
(0.61)
0.62
(0.61)
1.81
(0.77)
F2,103 = 39.83, p < 0.001 PD-N = PD-MCI < PD-D
General Activities
Muddled 0.19
(0.50)
0.59
(0.99)
1.54
(1.10)
F2,103 = 19.32, p < 0.001 PD-N < PD-MCI < PD-D
Preserve 0.21
(0.51)
0.49
(0.68)
1.67
(1.05)
F2,103 = 32.49, p < 0.001 PD-N = PD-MCI < PD-D
Learning 0.56
(1.01)
0.84
(1.03)
2.17
(1.01)
F2,102 = 20.37, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.32
(0.55)
0.63
(0.65)
1.79
(0.79)
F2,103 = 41.45, p < 0.001 PD-N < PD-MCI < PD-D
Medication
Simple Medication 0.58
(1.03)
0.69
(1.13)
2.39
(1.16)
F2,102 = 23.24, p < 0.001 PD-N = PD-MCI < PD-D
Complex Medication 0.37
(0.85)
0.44
(0.88)
2.17
(1.24)
F2,103 = 31.38, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.48
(0.84)
0.56
(0.97)
2.25
(1.11)
F2,103 = 30.73, p < 0.001 PD-N = PD-MCI < PD-D
Social Functioning
Forget Significant Others 0.12
(0.40)
0.09
(0.29)
1.19
(0.98)
F2,92 = 31.12, p < 0.001 PD-N = PD-MCI < PD-D
Forget Events 0.26
(0.62)
0.30
(0.52)
1.42
(0.88)
F2,101 = 27.82, p < 0.001 PD-N = PD-MCI < PD-D
Forget Names 0.60
(0.86)
0.92
(0.71)
1.57
(0.95)
F2,100 = 10.21, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.33
(0.54)
0.49
(0.46)
1.39
(0.78)
F2,103 = 27.40, p < 0.001 PD-N = PD-MCI < PD-D
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Telephone
Remember Frequent 
Numbers
0.69
(1.19)
0.69
(0.98)
1.96
(1.19)
F2,92 = 11.18, p < 0.001 PD-N = PD-MCI < PD-D
Recall New Numbers 0.69
(0.95)
1.48
(1.15)
2.41
(1.10)
F2,89 = 18.84, p < 0.001 PD-N < PD-MCI < PD-D
Average for the Category 0.66
(0.84)
1.01
(0.98)
2.13
(1.00)
F2,99 = 18.89, p < 0.001 PD-N = PD-MCI < PD-D
Reading
Newspaper 0.24
(0.73)
0.62
(1.21)
1.40
(1.39)
F2,96 = 7.90, p < 0.01 PD-N = PD-MCI < PD-D
Concentration 0.37
(0.79)
0.65
(0.95)
1.64
(1.29)
F2,99 = 12.59, p < 0.001 PD-N = PD-MCI < PD-D
Recall 0.12
(0.33)
0.39
(0.79)
2.00
(1.26)
F2,91 = 41.87, p < 0.001 PD-N = PD-MCI < PD-D
Learning 0.28
(0.55)
0.59
(0.87)
1.62
(1.32)
F2,90 = 16.12, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.27
(0.47)
0.59
(0.67)
1.67
(0.98)
F2,102 = 32.46, p < 0.001 PD-N < PD-MCI < PD-D
Organisation
Aviod 0.28
(0.70)
0.59
(0.82)
1.71
(1.20)
F2,103 = 21.15, p < 0.001 PD-N = PD-MCI < PD-D
Directions 0.43
(0.74)
0.74
(0.94)
1.70
(0.97)
F2,101 = 16.02, p < 0.001 PD-N = PD-MCI < PD-D
Multitasking 1.05
(1.07)
1.30
(1.13)
2.21
(1.02)
F2,101 = 9.21, p < 0.001 PD-N = PD-MCI < PD-D
Misplace 0.91
(0.97)
0.97
(0.85)
2.04
(0.75)
F2,102 = 14.51, p < 0.001 PD-N = PD-MCI < PD-D
Forms 0.41
(0.70)
0.82
(0.90)
2.08
(1.44)
F2,101 = 22.75, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.61
(0.60)
0.86
(0.67)
1.95
(0.70)
F2,103 = 34.52, p < 0.001 PD-N = PD-MCI < PD-D
Food Preparation
Non Simple 0.35
(0.80)
0.28
(0.66)
3.05
(1.28)
F2,94 = 78.83, p < 0.001 PD-N = PD-MCI < PD-D
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Quantity 0.41
(0.94)
0.17
(0.38)
3.14
(1.35)
F2,93 = 83.27, p < 0.001 PD-N = PD-MCI < PD-D
Seasoning 0.43
(1.04)
0.16
(0.72)
3.00
(1.62)
F2,89 = 47.35, p < 0.001 PD-N = PD-MCI < PD-D
Ingredients 0.35
(1.08)
0.38
(0.87)
3.32
(1.29)
F2,88 = 58.51, p < 0.001 PD-N = PD-MCI < PD-D
Variation 0.54
(1.22)
0.83
(1.29)
3.45
(1.10)
F2,84 = 40.65, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.47
(0.99)
0.36
(0.59)
3.15
(1.14)
F2,95 = 75.29, p < 0.001 PD-N = PD-MCI < PD-D
Travel
Get Lost 0.26
(0.88)
0.36
(0.99)
0.88
(1.26)
F2,103 = 3.04, p = 0.05
Overwhelm 0.47
(0.85)
0.86
(1.02)
1.58
(1.28)
F2,100 = 9.19, p < 0.001 PD-N = PD-MCI < PD-D
Landmarks 0.55
(1.21)
0.94
(1.35)
2.14
(1.62)
F2,96 = 9.78, p < 0.001 PD-N = PD-MCI < PD-D
Map Reading 0.36
(0.82)
1.03
(1.20)
2.48
(1.44)
F2,95 = 25.35, p < 0.001 PD-N < PD-MCI < PD-D
Touring Unfamiliar Places 0.60
(1.04)
1.80
(1.55)
3.78
(0.42)
F2,92 = 53.29, p < 0.001 PD-N < PD-MCI < PD-D
Map Follow 0.33
(0.75)
1.06
(1.28)
2.68
(1.52)
F2,96 = 29.92, p < 0.001 PD-N < PD-MCI < PD-D
Average for the Category 0.44
(0.78)
0.97
(0.95)
2.23
(0.69)
F2,103 = 35.81, p < 0.001 PD-N < PD-MCI < PD-D
Driving
Familiar Route 0.49
(1.12)
0.82
(1.47)
2.44
(1.85)
F2,99 = 14.24, p < 0.001 PD-N = PD-MCI < PD-D
Average for the Category 0.49
(1.12)
0.82
(1.47)
2.44
(1.85)
F2,99 = 14.24, p < 0.001 PD-N = PD-MCI < PD-D
Abbreviations: ADL-IS = Activities of Daily Living-International Scale; ANOVA = analysis of variance; PD-D = patients with Parkinson disease with dementia; PD-
MCI = patients with Parkinson disease with mild cognitive impairment; PD-N = patients with Parkinson disease with normal cognition.
+ Values are mean (SD)
* p < 0.05 for post hoc test
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Appendix 6
Number of patients who scored from 0 to 4 on the 40 ADL-IS items and the reasons for the 
elimination of ADL-IS items for 1.5SD:1 two-domain MCI criterion
PD-N 
(n = 43)
PD-MCI (2)
(n = 39)
PD-D 
(n = 24)
Reasons for Elimination
Conversation
Converse 43 39 24 Influenced by PD Motor symptoms 
Wordfinding 43 39 23 5% missing data in PDD
Recreation
Operating TV 43 38 22 Influenced by PD Motor symptoms 
Recalling TV 43 39 22 5% missing data in PDD
Self-Care
Cleaning clothes 42 38 24 Basic ADL
Household Activities
Placing Items 43 37 24 Influenced by PD Motor symptoms 
Household Tasks 43 39 23 Influenced by PD Motor symptoms 
Confusion 43 38 24
Complex Items 43 38 24
General Activities
Muddled 43 39 24
Preserve 43 39 24
Learning 43 38 24 Less relevant to PD, especially PD-D 
when compared to other two items in the 
same category
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Medication
Simple Medication 43 39 23 5% missing data in PD-D
Complex 
Medication
43 39 24
Social Functioning
Forget Significant 
Others
41 33 21 5% missing data in PD-MCI, and PD-D
Forget Events 43 37 24 5% missing data in PD-MCI
Forget Names 42 38 23 5% missing data in PD-D
Telephone
Remember 
Frequent Numbers
36 36 23 5% missing data in PD-N, PD-MCI, and 
PD-D
Recall New 
Numbers
39 31 22 5% missing data in PD-N, PD-MCI, and 
PD-D
Reading
Newspaper 42 37 20 5% missing data in PD-MCI and PD-D
Concentration 43 37 22 5% missing data in PD-MCI and PD-D
Recall 41 33 20 5% missing data in PD-MCI and PD-D
Learning 40 32 21 5% missing data in PD-N, PD-MCI, and 
PD-D
Organisation
Aviod 43 39 24
Directions 42 39 23 5% missing data in PD-D
Multitasking 43 37 24 5% missing data in PD-MCI – Not 
excluded
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Misplace 43 38 24 Less relevant to PD, especially PD-D 
when compared to other two items in the 
same category
Forms 42 38 24
Food Preparation
Non Simple 40 36 21 Influenced by PD Motor symptoms 
Quantity 39 36 21 5% missing data in PD-N, PD-MCI, and 
PD-D
Seasoning 40 32 20 5% missing data in PD-N, PD-MCI, and 
PD-D
Ingredients 40 32 19 5% missing data in PD-N, PD-MCI, and 
PD-D
Variation 37 30 20 5% missing data in PD-N, PD-MCI, and 
PD-D
Travel
Get Lost 43 39 24
Overwhelm 43 36 24 5% missing data in PD-MCI
Landmarks 42 36 21 Influenced by PD Motor symptoms 
Map Reading 42 35 21 5% missing data in PD-MCI and PD-D
Touring Unfamiliar 
Places
37 35 23 5% missing data in PD-N, PD-MCI, and 
PD-D
Map Follow 42 35 22 5% missing data in PD-MCI and PD-D
Driving
Familiar Route 41 38 23 Influenced by PD Motor symptoms 
Abbreviations: ADL-IS = Activities of Daily Living-International Scale; PD-D = patients with Parkinson disease with 
dementia; PD-MCI = patients with Parkinson disease with mild cognitive impairment; PD-N = patients with 
Parkinson disease with normal cognition.
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Appendix 7
Tolerance for the five ADL-IS Individual Items for 1.5SD:1 two-domain MCI 
criterion
PD-MCI vs PD-N 
(n = 82)
PD-D vs PD-MCI 
(n = 63)
Household Activities
Confusion 0.570 0.616
General Activities
Muddled 0.760 0..685
Medication
Complex Medication 0.687 0.735
Travel
Get Lost 0.803 0.901
Organisation
Multitasking 0.499 0.576
Abbreviations: ADL-IS = Activities of Daily Living-International Scale; PD-D = patients 
with Parkinson disease with dementia; PD-MCI = patients with Parkinson disease with 
mild cognitive impairment; PD-N = patients with Parkinson disease with normal 
cognition.
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Appendix 8
Optimal Diagnostic Values: MoCA, Muddled and Complex Medication for for PD-N, PD-
MCI and PD-D for 1.5 SD 1 two-domain MCI criteria*+#
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* Separation between PD-MCI and PD-N, see Table 18
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity 
is no longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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Maximum Accuracy (Youden Index): MoCA, Muddled and Complex Medication for PD-N, 
PD-MCI and PD-D for 1.5 SD 1 two-domain MCI criteria*+#
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* Separation between PD-MCI and PD-N, see Table 18
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity 
is no longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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Appendix 9
Optimal Screening Values: MoCA and Average of 4 ADL items for PD-N, PD-MCI and 
PD-D for 1.5 SD:1 two-domain MCI criterion*+#
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* Separation between PD-MCI and PD-N, see Table 18
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity 
is no longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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Optimal Diagnostic Values: MoCA and Average of 4 ADL items for PD-N, PD-MCI and PD-D for 
1.5 SD:1 two-domain MCI criterion*+#
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* Separation between PD-MCI and PD-N, see Table 20
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity is no 
longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
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Maximum Accuracy (Younden Index): MoCA and Average of 4 ADL items for PD-N, PD-MCI and 
PD-D for 1.5 SD:1 two-domain MCI criterion*+#
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4.00
* Separation between PD-MCI and PD-N, see Table 20
+ Muddled and Complex medication scores can vary from 0 (never has difficulty with the activity) to 4 (activity 
is no longer performed).
#The dark grey areas represent the PD-N region, the light grey areas are for PD-D, and the blue areas are PD-MCI.
